var title_f2_59_2992="Primary CNS lymphoma MRI";
var content_f2_59_2992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI scan of a patient with primary central nervous system lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 339px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFTAS0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiitrQvDmoazIq2sLFSfvEcUAYtWLe0nuXCwxs7HsBmvXvD/wm3FWvnaQ/wB1BXqfh74dw2kSiG0SFV6u45+tAHzvpfgDWL0KzQGND3auu0r4ThxuvJXI/wBkYr34aLZ2wCpdLJ64GAKkmu7COLyzcQb0/hHU0AeR2vw38PW8YFxBJKfXJqZvBHhaN8LplxJx23V6HJ4hihukZbOAhDyXPBq/L8W7DSo/+PHTBt4JAGf0NAHl7+CfDEkJzo11Fjncd1Yt98MdCvEZrG7e3k6BGr3Gz+POgSRAalDAyf3Y+34HNaen+MfBfjUtZxWcdvGTn7QVVCD+FAHyhffCrVIp9ls6TIejCqFx8MfEMS7ltgw9mr7AsPCGj63qF8uj37ItqQoGd27jr9Kevw/1SOR8yRugPGCOaAPia58Ga7bth9PnPuqk1mX+l3Vm4WW2ni4GRIuOe9fb+o+ENWtIQ8hjGT8oGDmsi/8ABOqXFsJZtCS6Q9xgk/h1oA+KSjDqDTa+tpfB1h5L/bPC5QLwT5RGK47VfhboOqtIbCRrKc/wseAfpQB89UV2fiv4e6xoEjFoTPbg8SIMiuOdGRsOCCOxoAbRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXWfD/wvN4i1RAEPkIfmOOtAGp8OvA0uvXSS3CEQ54X+9X0v4Z8HWem2iJMscQUfdXtVTRNHTSrKG3tIF8xeCwHArorWw1DWZxbaWo3KP3sjHAWgC/FdafZri2aJJB/G/asXXvEMJUL55nm/2eFql4xPhLwZYNcazq4vtQA4t4myM/nXzP44+Il7rd1LHpq/YbHJASPqR7mgD17xH8Q9Ksle2u5lUjqsHJz715br3xMe4dk0yyjjQcLK/wB6vN3dnYs7FmPUk5ptAGvf+I9VvifPvZSD2DYFZjTSMcs7H6mo6KAHiRx0Y1btNVvbQ5guJE78NiqNFAHoPh74qa/ocySWdwySKMFwSCfrXo1v+0nrnkxiVjvUYJCjn6188UUAfTMX7Sc1xEiX9urle5Xv+FFr+0le2048ra8Gf9XIuRj2PWvmaigD7Z0L9orSdSUJdW8UTnggscH866xbvwP4u8uWSNYbluN8Y2kH6jj9K/PtWKnKkj6Vv+H/ABbq+hTrJZXTgA52k5FAH2JeaDqunNPGbUX2m5IDHlttec+LfhnpOvQyTWMH2S55wMY5rR+F3xnt9UWO11W6Nte8bS5+UmvWZNR0/XLZomtEh1HcNroPlkHrmgD4T8U+G7/w7fNBfRMoz8r44NYdfZ/xI8GLrGlTWN9AqXSruRsc18ha/o9zouoy2t0hUoxAPrQBm0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFOVS7BVGWJwAO9AF7QtKn1jUYrS2UlmPJ9BX1J4C8NL4f023jgg3uR8zAVzXwM8FxWKR3eoKBPJ8xz2HYV7W1zaWyz3OpTJa2ca4BA60ARy39u1j9jhg8vHLzeleT/EP4pPpKy6P4XkYSkbZZ06msL4nfE0Xkp0zw2zZdsMy966/4HfBeXUCmu+K4yIW+aOJvvSH+goA8jsfh74w8YWk+o29jd3KLli5UnJ9BXmmo2U+n3strdxNFPExVkYYINfo7438UaX4D8NM48iJ0jItrYcZPbj0r4c1e2u/HXi291W9ZFkuZC7lBgdaAPPKK9dHw1tPI/1hL1Qtfh1Gl4ftDs8QPAHFAHmSqWOFBJ9qnezuUVWaCQKeh29a910nwRpNqyusGT/tHNdA+g2WNqQBl9COlAHzba6dd3UgSC3kZj2C1q3nhPVrS28+a2YJjJwOlfQdppMMMu6K3jj98U3VDGtpKrAMSMYoA+YHQocGm1q+IYfI1CVQm0bycVRtLaS5k2xqTQBBRXp3hXwDBe2okvi24/wio9d+Gc8TF9MfcvXY/agDzWlPWr+raRe6VLsvISnoe1Z9ADkZkYMpIYcgivWvht8T7ixaOw1qZ3hJAjnJ5T615HRQB92TauPEOjW5lc/aI1BjuByJB6GvLPiz4Li1zSzd2yqt5EPmx61ynwR8cyRI+iX7l0K5jLHpXuEOntPGxI3RyL19aAPie6t5LW4eGZSrocEVDXtPxl8DfZ2bUrBM45cAdRXi1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXpHwq8Jf2hcrql+n+jRH92G/iPrXM+CvDk3iHVFjAK20fzSv2A9K+uPh/4Ts00xbzUMQabbL8oIxvxQBTubmPQfD7XMixwREZ3tjgV8++OPH2q+LLwaZYSN9lLbQB1au4/aD8QC/s2i00lLMPsC+1cDoOiy6H4Yk12eFldhiJmGBmgDofBWn6J4VliutcljkusgsCc4/CvVvF37QJh0eKLwu1vDPGAuXj3ZUDGADwK+b/AA9pN74l1PfcM5jzl3PYV6bN4SsVsPLit0yRjd3oAw9f8eXHjmZl195Jbs8RlDhR7YrW8J6MNP2M+SxHPpWFbeH4tPv4ZM5+bHSvRbSHMaYxgc0AXzGGhBHC+1UmjO8kDH1rYtwPKAwBUcluSOx/CgCkJsR4HWrEU5YAbue+KrPbyByFWrtpCQQSAp/nQBJdS+VZu3J469K4K9upZpWwzBSa7bWzutSmecc4rj7iW3gjy5G6gDzvxLpLy3QIQsXPHqa3PCPh5IYVeSPEtR67qcXmo0bDepzn0rqNFuRJZRSd3HNAGnpn7mX5Tg9we9dJsSWFWzyBXLRv+9znkegrq9PbzbMcjNAHmvxM097mx/dx7tpycV5Omnb7lYjJ5ZJwSw6V9K31iJDtOCD14rl9b8HWEqPKItkhBO4UAeH6tp02m3RhlKsOqupyGFUa7BNDuby+e2Ub0Q4y3QVevfh/MIw8EgDY5U9KAOK068lsL2G6tziSJgwr6s+FHjP/AISKwjiLKrhcEDqpr5m0/TIbbXYINbV1tC+12Xggetd14YvIvAfj+JIZml024AaNiex6UAfRniHRxdWEqyx7gwIzjrXyP8QvDr6DrcgVCLaQlkP9K+2PCFwNX2282Csw3RN29682+PXghZbeeFI8MQZIWx39KAPkaipJ4ngmeKUFXQkEH1qOgAooooAKKKKACiiigAooooAKt6ZYzalfQ2lspaWRsADt71Ur2n4K+E55DFcpAZL28OyFcfdX1oA9C+GHg+0tLRbZRtggAkupvU9xXYeI9da7CRwkwaNAuEToZCKtFYreP+xbeIRWdr899cqeXb+7/OvO/GmtxXl4wtP3dpEMIvbA70AcF48aTxB4j0/TbZOJJBmNfTNanx71N7a30LwtEojhtowWC/xHHeuK0nxwmk+LJdTWDz5I8rED0z61Dr/9reJLuTW7qNzJK2V9APagD0HwZYR2WnxhVA3AE12CQLKg2dq838MavLHEkN0jI6jbyOtdrYaijbV8zDGgCtqOkSSzK0fAByQa2LK3+QdgKuwt5ig5H409mCr8qCgBBwdoyamXJYZ4qCPPLdzVjHyg55oAUqCpAAz61Gcp1A4oXLHCjpT3xjgfnQBhaoj3DssedprNGgANvbJPpW9PKsTtxk1Rn1CZQQq5P0oA888deHlS1N1CMPGcsB3FSeHJ9+kwqp3FeCPSp/GuoXVxFHZiMoJWwT61p6N4agtrWNMksRljnvQA6KdVA55rqfD0yyRfMMg+hrGTQEbBDNkdq3tI09bNflzz60Aas0SqNy1zfiK5ZLWQDDHHAFdIygrzWDq1gZtwwcetAHOaHYFYA5UbycmtwW+YSWHFT2NngKBxitGSDCbMA56mgDy/xbokmoLm2gBkU8HHWvN9dhu4nC3jMJIRhA3Ye1fSi2QRSGAC4rzn4o6PDNpbXQVRNHwD6igDqvgH4nu9UsDaC4b7dZEPEhP3gK+j/E1pF4q8HLd28S+fsEig9Qf4l/nXxX4bstS0LQLPxVpGV8mQpMFPb3r6a+BXxCttZiks7iVUEv7yPJ6MeooA+Wvi94dbTdXN5FHtjlOHAHAavO6+yf2hvBVs8cjWxwblTIqH+Fh6e1fHVxE0E7xOMMhwRQBHRRRQAUUUUAFFFFABRRTkUu6qoyzHAFAHR+BNAbXNZjV1/wBEiO+Vj0x6V9c+GLMeGPB0uvTtHCZh5FkgHzc8bhXl/wALvB5+y2mmQjFxORJcSY+6Peut+IesR3GoxabbS7tN01RHHg8Fu/60AZmp63LFbSWsEhKyHzJiTy7GvKPiLrbW1mtrAds0/wB4g9Frr7qTGXduOp+leMeKr8alrc0kefLB2IPpQBo+DNBfU7guy5jTkmvU4LWS2t1iKjaOg9Kzfhzp32XR45GUhpPmNdu1oksJIXr70AZcVnHKA2xT61Yh0uMSZXg9RU0MUkDFVXK1eiJxnHSgCxaIIkA6k1YYcHmoIAev6VPxnk5xQAka9s5FTDoPWogfmytPySPSgA3bWPPPtTmZQuSflqMnPPeqOqFxFlSQPagB80lsrfN82aq3MkOMxjNY0rXT5AwPes3V9Nvr20aGO88jd1YcUAO8ThHktFiCvcBw3HYVrxagI1QkbGxgg1g+F7D7MzRzzi4lQ43k5Nb15aLLGQTz1FAGlY6nBIdoZM/Wte3l8zHb+VcKmmIJQwLBuxBrptKkkUKjHOPWgDYPyk57U0/NwcZNOcA98mmjA5PWgBQihCABUch2fePFEkqxIzGsC61AytxnAOKANC9usrhD7AVxPi+CS9spVYgbRnGa3/NUHLng+9Zes7J7eQI3JUigC98Axp/iPQPEHhPUJljupYzJa72wpI6ivNdJ1C88C+LfIlO1Ek5APGM1nWkl9oGqJqdk+1oX+fB7V2PxE0keJPD1v4i0spJkZkUfeB70AfT8xsfiL8OItQtTtubWMsp/2lXkfQ18cfFnQ/7P1gXkS4iuOoA6NXrv7LnjMWM0mm38hNrL+7ZWOQPQ1Z/aA8JLtv47Rf3I/fwc5+tAHy3RSkEEg8EcUlABRRRQAUUUUAFdj8N9FXUNV+2XQAtbb5jn+JvSuPAJIA6mvpD4U+GrCG00+DVzsskAuLll6nPOKAPVNIT/AIRL4WXWqMAmp6p+7hbPzBT0/QE/lXkJiMY2NL5x+8xPc967Lx/4tt/FF5Elooh06wUxW8anr7muIEixKSe/WgDI8T3IttIvJCwXCEA+5rxq0Ae6iDHgsMmu/wDinqSyi2tIDhPvOPU1wECksD1+lAH0PoaxR6ZarG25Qgwa2YblcY5x7V4l4d1zWY41t7FS6jgBhnFdTaXfia2Pmusbg9jQB6Wk0Z4OOfWpo9mQOoPf0rgrLXNQLAXtoct/Eg4Fa39sRpH87GMn+8aAOrR0BwpFPVRyeAetcvDqauABKrYrb0+cSdCTx3oAtvwMdz3FPHTBNNIBA3Vk+INRbTrGaZfmCITQBrHGOOPemsVK7XA968m8O/EqSTUBDqKqIWbAx2r1KKZZlWRcOjjIIoAZNBAi7+AOuDXDeO/EC6RZ/LHveTIXHb3rvpFEseD+tY2teGNP1SHFyjFh0oA86+GNyb+e8mlLBwc9eK9TtIlki+YZPY1h6N4Ut9G3izdgr9c10VlG0alWOB60ALFYq/JOParMUUafdXHualjI8vil3KOcHNAD1wV6imH7x/nTk2ls+tI4O7LdPagDM1mdYYMAk5rlpHmcNt4rrr+1W4XJ5FZsmnII8qaAOQuLTVXkLJMAnYGh7bUzblAYie7EV0hiK5z17Um0kYXknrQB5lqWhagBJnDhhzisPRtfvvDpuLOYM9tICDGx4B9a9r+yK0eGAPevOviVocaQLdRAbs7WwKAKvwxuHTWbieCTaF+fA719F67qsHibw1bXMcWLizXZOvdlPevln4cXYtfESIxwsqlDX0N8NtWtbHXli1JPOsrlTDKnse9AHzl480n+yfEM6IMQynzIz7Gucr3744+EfLS5aGJg1s5eEEfMYjyP0rwI8GgBKKKKACiiigDV8MWZv9ds4AM5kDEew5r670PR7ez+H2satex8BBHCDwGNfOXwb0hr7XJLnHEI2qfc19OfFqV9J8GaFoCuA8yiWUAdf880AeOW2VG1QPmJanTHK84BFAGCzr0HArD8WaqunaNK/wDy1kGxPrQBxGs30epeIZtsYeGMFQT7VmaXYT6hqXk2UeTn73YCtKe406y8MRx2+JNQuSWlf+6PSus+FkEL20jADzAevtQBoaPoc2lwZc/OepA4rT0zWbeS9e0mJSRem7o30rpjbLsBJBU+tYusaBBdYlACTLyrL1FAFx1XyCU2qK5vUNOju5w0jnPYA1rW8kscOyQZ46ms5riP7YIiwWRugoAs6NpkUDnYTj3NdbbBYYxwKzrCAKg3fe71aZ8vxwBxQBcW4OeQM5qlqsC3lpLC/wB11Kmn28MszgICTVi4t5IIwXjP1oA+cfEeh3Ok6hKpRtgYlWHpXffDHxfs26dqD+0bMf0rtdd0i21K2wUGfevIPFPh2bRbsTwlgmcqR2oA+gFbcA3G096kj5GDg8cZrzX4deL/ALZEljfMDIOFY969F3FjxjNAE25QuCMj2qKQjPGcUSMFyzkKAPWud17xTZacSPMQsOwOTQB0klwkKAs4GarR6vZyXAi8wBs8CvF/EPj6e5ZltRtHIzWNomu3susW7M5LM4H60AfSPReOnan7yygZ4FVbQyPaw7+pUZNNurmO1Tce5xigC0+dvAxVCaMtw2RThdiQbo+fanli4+Yck0AZk9uFBySSKpOJVwqJ1710fkq6+9RG3BXJ49aAM1HZUwRg964j4ib30uQJgAHmu/uLbb0bIrlPFemS3ljKqDnGfrigDxXSzLa38VyikiGQEmvddOvGH2a4jGGjw6+9eO2F/BYzajbXkGfOQop/uN2Nem6I+/SrJ8kZTBoA9p8U6vpHjPw7aXoPla1bp5c0W3iRe/NfJvxB0UaPr0giXEE3zp6D1FfQfw8u7CDWTY6pGZYZwVDL1UmuF+LugNMl0sUbl7Vy0eRyVoA8PooooAKKKuaRaNfanbWyjJlcLQB7x8BNF2w2QnzH9plDM2Oi56/lXafF7XG1XxZJHE6SQWMYhjdRwe9dP8JdJttO0HU9R+UCxtyiBxkZKmvJpfOvLh5SDumcsaAK28omD3ry74i3Zl1gWwY7IV6e5r0rUnWyWV5D8kQyc14nqd219fz3LnJkcn8O1AHS+DPCTa7E808pihHCnGc112h6XceE9VVC3mWM5278cg9q2fhnp723hqBphhpDuC+1dRd6etwmwqMdge1AFlAHgxnIxmqy3Ajl2SdD61bsYjBCI3PC8ZxWN4itp5rVzavtdeVPvQBdeFWJKgHP6Vy3imxCGO7gwksJ3A+vtWda+NWt5xZ6nC0NwvyluxrYguF1O6aJ/nQc5HSgDT0DUk1Cw81ARgbTkY5rQiAzgHcxPSmw2qQWqpHHsX0ArR0G3WfUY0YDGaAOw8P6eq26P5Y3kVpXOlC5UpMg4HGBWpHYiK3jWM7TinQh1bl+OlAHlviDTnsJm28J2rl/EWnx6hYOjgE4r1jxpZLNaFsgkDOa83kUFWXqMEUAfPySy6RrTbDtZH4r2fT9deS2tJiQAyAua8c8axiHxDcqpyA1dE1+bfwOr8hnJQGgCx4x8eXM80tvZPtjBxkdTXn9xeT3DlpZGYnuTUDEsSScmhVLEBRkmgAALHjJNdh4C0aS71aB3UhVYHNN8P6C9yquY+K9V8JaOlmodVGetAHaIojjRM9BiszWk3IQc8c1oISXBHU+tVtSQlOTk0AVdP2KgIJOa0sI2CD+FchczzWEw53Rk9K27K+jltw4YYx0NAGmZQiEnFZ2oapHbxqXfP4VBc6hAOAwLegNCRRTw72AYnoKAHWmr296reXIrEcEVJcMhhOePWudvrJLaUvbJsLHkAUsun3t1asjXDxKR260AeQeOooo/EFw1ucxk9feu48C339oaJHErfvbfhh7dq4zxnpk+mXXkzHeCdyv61P8N7gw61IgOPMjIoA9Qtrp7PUYbhCQyMMmvQfHQXUtNtb7ZtLxhGKj7wrzckFWzkmu60O/mvvBc8ezmE/ePOBQB8yeJ7D+zdburcDCBsr9D0rKrsvifbCPWYpx/wAtY+fqK42gArq/hnbfaPFMBK7hGpf8a5Svavgp4Yee3S5xia7kCoSOi560AfQF866L8FJXViJdRfbz/vf/AGNePWc5gyHI2qMV6H8ZdYhWXTPDNm6G2s41Z2U9XxzXmUnyZB5z1zQByXxF1EW+lNCh+e5O38K840qET38KN90tzW/4+uRc66IA+EiUA+gNYFg5jdnUEuBgYoA+jdJeOG2gVMeWqAD8q0opgWBzyTXjvh7XrsrHBMWbHA9q9G0eaVhmQkgjigDpZm3JgfnWPc3KK5WdsL61oRO20BeQeuayPEFss9rOHYjKnGO1AHLeKtLtL795EgeQdG71qeDbAWtqMsSzHBJ7Vznhl7mTdBLl1Q/KT1Nd5psDqVB6H0oA1ZYh5QOcgdqdok622pxu/AzVlU3RhQOKozWxEm4cYoA9ct7gS26ENkEU/egGAOvWvN7DW54IBGwJA6GtEeI5VXkZWgDV8WgfZuD26ZrzCWRR5vPbmuj1nV3uIDt79a868WamthpdxKzfOVwO1AHkXi25W6166dPu78CtbxF+58JaXEchnYviuV3Ga53NyWbNdf49xHYaPEBjEIOKAOLrZ8OWYubpcjqeKxq7n4f24lnDYyBQB6HoGmpHEiBCBiuss1ESADiqdhAsUa5zkitKLAwQOKALKgs2T09qgvGCgluRUyMN4A4A681FdjIYnkYoA42/1EvPJBBas57NjgVBDol1cgtcXLxqf4VOK6WG1TzN2MFvatCBFHDAcUAchb+GDFJ5kNxIW5+8etbumxPFHskBJHFajKAc7RTMgAsO9ADWRTxgbqhneNE+bG2mXcxiG4DmuG8U+J3s1MRQgnoQOKAOZ+JdytzqkUaLwgwTXN+Fy1r4kgA4O7FPvJpb64aUhmB7+lUbWY2uuRSns4P4UAex7T5hXPHWvRfg2llcz6rYajLsR4WZBngkV50khIVlxhwD+ddj8LJoIvG1v9oiaRGRh5a/xHFAHkfxft9rwOv3UcpXmle2/HmHm42wGHZcE7COVrxKgByLudVHc4r7P+AmjwF7SSSRUhs4BJtPQnjv+Oa+OdIiE+qWkZGQ0qgj8a+7vgrp9tc6HfRTx5VoxF0/hIOfx6UAeffGWz05PHgn025Sf7QgkkRCCqN7EVwOoS+SkkjnKoCTWlqenfYvFWpW6SvKkEjKpfriuZ8ZXJtdFvJARkrtH1NAHkepXBu7+4nbrI5NemfDPw9byaeLq5iDyyHK7ugFeVoNzqPU17p4Svba10i0jdwvy8DPegDZk0G1dg4jRGXptFadraIiYXPSoPtikbiAI+u7NWINRt2ACyrk0ATW6lXOckVU1y2lltpFibBcYHtV6Eqz8OOadKQMFuf6UAeceHfN0fUjaapE2XP7uUDg16JZsrxkjHHQ1RvraC5Ug7TUOmLJDOELZQH1oA6VCViBwT602UbjyQBUqY8vg4z196rtgdOAaAIlXnOac6ZAIPNOXBznvSNgfdJoAztSYQqQPqTXjPxK1FpphCGyoPavWteYRWzs5ycda8D8Qyve6m/ZdxoAztKj83UIExnLj+ddV8UDt1K0hxgRwgAVmeELEy+ILdTyFYHir/xQYnxGwPZAB+VAHHV6T8MEIDvkcdjXm9eg/DaYNIYgOaAPYowWjXPPFXIlJVQAR/Sq1oMRDdVxWJTj7vagCN2KkjG457U7exGApxjoaFVhnpSlVJ+ZiuKAFjiO3ORj3pA/yk46UKOOmQO9IRuBGeaAKs0uSCc1E9xtHBwKfdx5UgViXtrdTjbG238aADVtSVYnBauHbT7nxDcnHCKcDIrprnQJ53UNK2wfeHrW7p1glnEERQB3IoA831vwzeadZtNHIjRqvzADtXnd22bsn0Ir6G8SRodJuwR8piPevni9AF7IO26gD2nTxvsrQqcgxKePpXQeFLlrLxnpUqMUHmqCR6ZrntHXbp1nsxjy1/lW5obqnizSnbGwTLu9MZoAZ+0go+26o6NvV5t2SPevnavqD9pO2tXm1CWzdWjkCvlRgZz0r5goA6HwBbLd+K7GNhkBt35V97fDKKHSPB813KWEeTI5AzwB2FfBHgG7Nn4rsJR3fb+dfoT8N51vvBtsHQbRujI/vD/JoA+cvFGoW2peNdavrBt1tPIXU4wa8v8AifdbNNigBGZZMn1wK7/VbeKz8SatHECqJMwVfxry74qt/p9oM9UzigDirSJpp1SMEsemK9P8NwT21pGl/CCByjHtXNfDLThfa6XcZWJc/jXrmp2iR25fbwKAMyKePaUlkCoe2auW0NuOYmHHfNcbqGjXF3MZI3IbqAKZFp2vWyB7eVm2/wAGaAO4W4kjk3I+VHY1dkvhLBjfgkV59Z+KXjmFvqkRifOCSMVurqloy7llXPbmgDP1DxHLpl+YTmVO3Na/hbWbi/vRtt3Ef8TGuJ12YHVxNKuYc/e9RXqfhEQTWUclrjGO1AHUHiJR1471VbLD5iAc8VOx+Uck1W3MXwOQKAHqGLDB5HWlkATPJ5HNOQMG+8cmorkllIc7V7tQBx/jOd5YPs0OW3dceleY32juHaVVOxPvE16xrixRRNNI4WJRyx6tXGfaFe0vrmVCsG3auf4qAM34e2ofVpZwCQgxWd47hNz4juHfICgZzXZ+AbFrfS3uCpBl5H0rl/HKsNWu1jHzMooA4GQYc46Zrufh5PaW84LOfOJwB2rhXDBiGBB9K0/DtwbfUYW6gMM0AfSFk29Eb2q6GGCQOKyNFlElsjIP4ela24lNw6+lACBjj3p7IHxnrUYfI+YEMKkR2OeKAHMfTPNR7drEnIJpfm69PakkB28k0AIMc7hzTCqE8LTH4y2e1MWfCAA0AKcchR3qOVtv3sCq13fQ2wyZBu9KxnN9q7vmQw2/YjqaAKvjDVY0064ghBkdkIOOcCvDbk77mQ44LV65rmnXehxSXFnJ50DczI4zkV5NczebcSsqhQ75x6UAeyaKvl6ZaqjZAjU/pWxo8e7xJpijDfvBn86x9FJXTrUMMfu1zn6V1XgS1Gp+OtLgdwkYkUsT0xmgDY+PFo2buF4zGgh3ADpXyk4w7D3r7E/aNeMXd2IgAEt9px64r48l/wBY31oA0/CqF/EWnAZ/1y9PrX6FfCM/8UbEO4lcfyr8/PBAB8U6eCQP3gr9B/hVEsfhKEqc7pGJoA+YdSmeTxNqqyHJ85snHPWvOvGdqNR8Y2NpLIERowCx7V6l4rsfsPxF8QQE4/0glR7V4z8Q5CfFLbCQyKBkdjQBv/COFFvL4g52ttB9q9YuYFntiuMg15F8IHIubkbgASOK9jg+dNucUAcui/Yrh1kH0JrTtDHIgIIyetX76xSZWDKGz0Nc9cxXGmyBwN0Y647UAWNX8LWOqsjXEfzDkMBg1han4OtlQCORkA6EGun03V47nAjcEjgg1pyRLcIckYI54oA85fwm08W1ZdyAdzXTeD4ZNLT7Iw4z8pq6sBtpSigla0bKDMgkdMgdKANIsD2xVfGJiD2qyFBUZFNCqrc96AGCTHTrnvXDeOvFS2rC3t3BkB5weKtePPFEWiWckcRU3L8KO4rwq61Ga6uGkmYszHJNAHf3OqSa1NBDI7MONwHQVW1S5bVdWg061b/Q4iFwv8XuaxbaSYW8cdoOZB8zAc113hPRXhlSRx8/XNAHd2NqsGnwwJxjA4rzz4jWpTVDMuckda9IR9hyTwBxXNeJIVviw27vxoA8WvjvOSMEUywfZcKfet3xDp/lMwVcAGucGUceooA+hfBtyLnTYiDyV7V0mSuFIOa8w+FuppJi3ZtrA/nXqm3AboaAImyCM9Kni9DmoEYs/PKirS4IyDzQAkqqOxyajKkjk5FTOpzu/OoicH5cmgCreK3l8Zz2rDuYJ+MOQT6V0rjdjJ4prQoy9B7GgDnINIXhpCXY8kntWpDCsa4AxiruxRHjIqEsCdp6dc0AYPikb9FvRgf6s189yDFww/2q+hvFUiQ6Rds7jaUIr57Pz3fHd/60Aez6XGRp9qCcny0/lXUeBtKutU8QqbebyQrrmQfwj1rnbJAtlb5PIiX+VehfA7TLvUvEmI8i1Ql5m/2fT8aAK3x3kcR3sIcXAih2+aP4vevlWX75r6y/aESK2l1SOBQkSpjj17ivk+RSWOBQBu+AbSW78VWKxDJVw5+gr77+EwceH5AxJXfwOw9a+I/gtF5nilyPvLESBX3Z8OLWS18LW3mnmQmQD0/zigD58+LiwW3xSvzCWzLtLZH8RHNeCavbvqXj6aFAGJkxj6Cvd/jxJND8VQ14vlwPtAI7jHBrg/gvpFlr/wAaWtrot5D+YQQeeKAOT+GbtbavcxEYIbGK9otcsARkg1w3iXwnP4M+LN9pxO+KRvNjfH3lbkV39opCLj09KAHRl2YqeBSTwCUbSAQRzkVKMlucjFP3Buv5UAcXqfhy6S8STTJRCM5kyOtb1jDOIwskntWv5aH3p0cCZBCYxQBXitYwAGyzDvVuJQkfHJNSCLjJIFG0BgRkUAR4yMiuY8ceJ49A04lVD3D8IK6aWQqjkLXivxRWWe8DZJAHQdqAOB1rUrjUruSe5kLO579qqW0LTyBFGSalt7OS4lwFOc16N4L8ImSRJZ4yTnpigBPCHhy4AVpWIB5Ar0qzsFtoB6kVdstOitFAEfIHOafcxgLkAk/yoAzZlVwIskGoptLUoSMjiqbPONTc7Tgjitm3ld8hufegDgvE+hF4WKrl/wCdeU6navb3DBlIr6Yv7JZocbQcivOvEvhdLiYkLsJ9qAPPvBeoNYa1bSZwm8BvpX0nGUkt0dP4wDXgNv4Znhv0UAD5ute8aSpGmW6tkuFoAfGNshGOamC5Y45ANOiHU471Ipxk7aAGSA7c9j1qFjxhRx3NTEc89TUSx5J28GgCGeQRx56iqD6pbxDEj7CegNXZ7Z2U4PvWVeaOlwpMnJPpQBFe6upIWM5+lVm1R9nyqfpVCSwaxuGQksjcgntV2CKN1wCM0AcR4+12ee0a2WMqv8THvXn9jbh5rY5G53HFel+PbJf7KlcgB1HB9a4TSIgb/TE2gHdkmgD1ZlaG0UscBUC/pX0F+z5apY+GL27lXasjg+YR2ArwNbQ3t7bWfmrEsrgF36Dmvq3wBpltoHg9LdL2G9t49zmZDlTxyP0oA+d/2hbpZYtTlgZmieT5efevmRidx619AfHe9U2MmzavnzHCjsK+f3+9QB1Pwt1VdL8XWrSf6uX92341+gXw+vI7zwva+URmPKMM8jmvzUtJWguopUOGRwwP4197/s/34utAkD58x0R/wAwf5igDgf2rdJkgvLDVkG6OZdjZ/hK//WIrwP4Qa1Po/wAS7K6tziTeVBPvX2V8etNsL7wDdy39tJM9v80ToM7CeDn2/wDrV8MeHrtdL8bWdxj5EnHX0zQB6hr3iG6134t3smpEGRPkHbj2rtYJdseScd68z8b3kFt8YftSfLDOFP5ivQROvlcnIoAmN3vYhe1SozuMnGKxZrlVfMbYbtWtYuZkUkkGgC5CGB5q4o+UAN1qNIuBlvwqdVK4DdBQAMSQB1pqseQR0p45Ydc0E9RjmgCG5TfER1rgPEOiG8lZdvJPWvRQi46EHuaiNrETvIBNAHm3h/wQscweYbuc16Ha2MdnAEjUfWrwCqucfTFI2CM4OfrQBn3UqpnfkYrN+0TS5EQOwd6tX8Jmkw7lcciqd4/kWzCJtrAH8aAKUL/aL5hjiPqfWtqJAo3A1z/hm9+2xSuY9jbipyO9dIsRVOVzQBNEoyT296qajYi4Thee9aEacDAxTsEtjHuKAOQXR8zqVyTurq4IxFAit1HFSNEFIKjDdaRz8oyOe9ACYCnOetSxj5RkcUzrnPSpAxKgdqAInAUkfw0zO3PUE1JjBJzUTlieehoAQHryKQKNmc1Rv7nyUbYpPpXPt4pS1l2XsMkSno+MigDe1CzS4Q71+YdDWVcaZLbJ5sbF8/wjqKls/EdldkLDOrHOPm4rQa4jIJDYz6c0AeY/ECWVdKVCGBkOOe9YGmWIj8RabCwO9VBYHsa6T4hzLfavYafAwZvMGfxqCwCN8RLgyPlYUyPwFAHf+F9GOu+JbazUO4DgEIOnPWvp06fY+F/CdxbWEYit4o2PzHOWPGTXkX7N9m0+saxqTYKKvlr3xk//AFq9O+J1+bTw60SYLTHH4CgD4z+NuoedrKWyMCiDcQPWvK2611nxFvftfie9fsGK/lXIk896AGjgivub9myZX0WIrzvt/wCRFfDFfYH7KGuRXGlwWrNiSMNGc+p5H8qAPd/HNq174Q1aBcZe3br7c/0r85vEsLWXiF84+WTOR9a/TG7iE9rNEQCJEZcHvkYr87Pi1pb6d4lu42ABWQ8enNAHQfGXT9+k+Hdcg24lhCuynnP+RWh4bub/AFDT7cKcptHzd6pJdx+JvhBJBjN3pzDj2FWPhLeLcaQYmcb4jjHfFAHWWmiyb1aV94610NvCsQ5IxUbzpFBvb8K57UtcmeTybGPzJCcZ7CgDp3u442YHG2nRXMcvIbr05rlrLTb2T57uQkn+Gtm1s2i/DmgDZjBUFs9e2aeNpXLCqa4LKCSx9KuDOz5sD2oAepBBFKuAeRxQueOwxRjr60APkVWXAGBUDlUjxnkVO/yg554rNnLSE4PSgBk2G5rOukBjfdjFXdhZRnj0qveRjy3GOxoAxtBKp5qjpvOD6109vKkg+boK5TR1OxiORuIFbUKSbgVyBQBs/KUwjUiqwYfxVVQMoBPBq7bsCtAD2yVXjFQsuCCwPNTSdDjkVVnnCJgD5qAHSMiqecVTe/RJFQnk+tZN7qjLcFUUk1k6nLPMQ6DntQB28bq6E8bj0puOa57w/dXBJWcE4HWuiDZGeOaAK8sJdz0qtcabHMhV4o5B6MKs3M4hBZsisu61yGFcndnsB1oAqt4cswSRAqNnggVHfacIbZkjlZSFJBz0psd7e3D71DBOorD8Ua7c2VnKpQbpAVBI6UAUPh34Wv8AXtZ1TV2zJbaSjTSO3t/+quV0q9eTXb+5bkykj8zXrmi383gz4E6ncrKI73WZDEUI5KEEZ/U1wXwl8M3PiTxHaWsK58yQFiew7mgD6k/Zz0p9P8GzTOpC3MoK56nA/wDr0/41aosNutuVA8qNpN2euR/9avR9H0+DSNLt7K2G2CBNoz+pr5t/aN8SJGbwQuC0hEcZB7AYJoA+YNduTc6jcTH+Ny1ZZ5qa5bLHmoKAEr1j9nrxIdG8Vi3MmxZyCpJ6MDXk9WdPu5bC9huYGKyRsGBFAH6jWky3NtFMhyrqGGK+RP2o/CKaZ4ha8tUYQ3a+bzyAxPI/Ova/gB44j8VeFLeCQ/6VAnPvzzWj8bfCT+KPCkhtl3XNqrOEx99ccge/FAHx18D723i8US6VqAJt9QjMJHv61Bcrc/D3x7d2Uqn7M7nHbKk8GuauXufD/iCO5hDRTwSZH4V6R8TLObxX4StPEyN51xGoEm0fw98/SgDTvPFNhc2IWGQvI3UAVoeHtjgOFGTzyOaxvhla2lzoEMxjQy5IYkZOa7M6WM7oQUPqKALyNyBjipZG+bjtVFLafIO7p61fjiaNeec0AOt+Parcanf68VDboTnGMH1pbqdYFJ4BxQBMW2yDBBHepAepXpWbBdrKM8nJ61ZEu3pQBYkclPTsKzbpjFnaMnuau7gRgn6CoZ4g8Z3dDQBkNfxjI3/MO1ZHiLUWgsJpuT8vAFbP9kRGQy7OfUVk+K4I4tIugeTsNAFfwlMLjSbeUnk8muh+2xI4Ga4jwRpc8ekxSNckh+QnoK620sCpyckk9aALMl3vwBn2xWlak+WKzWtmaVVUYA71rwpsVVOaAHSOdoJ5PtXOa21zH88Kkr3rpH4GNv41XnhDLyPzoA5ewEd5yRyeue1aiabHjIBOKzruI2N8ZIx+7f7w9K07e6O0Fjx6UAWba0WMHIwfapnGwDAy1EcvmHkACpdu4jcORQBVkVZlIcZ9qqNpsDPuKAketW5JQrMAMCoo7pWcjIPtQA2SPyIwEVcHpXn/AIhiOs+L9L0qMbmaRd4H1rp/FGtR6Vp0txKQSBhBnqa5j4cx3ofUfGF2h8mBG8tj2PtQBd/aC1mKfVdL8N6fEscOnQqjbf4mIzz+det/sxeFLS1sZdUmk3X8Z2LGDjaCOp9a+Z9Nkm1vxO97d75ZJpCcnnvX3B8JfDaaB4Xhd1Iu7tRLIWHIHYflQB0Xia8isdDu5pzhShQD1J4r4O+MeurqXiB4oWzDDlfxr6f/AGivE/8AZWi/Z0JV1G7OerEcV8QanctPcySOcszEk0AU3bJplLnmkoAKKKKAPTvgX45k8I+KrbzXP2WRwGXNffum3sGpWEN3aOHgmXcp9q/LZGKOGU4YHINfY/7K3xE/tbT/APhH9RmzcRjMW49cdqAPK/2jvBT6H4mu5Ykb7NM3mREjjaasfs3a3ZXMereGdbRZILq3dI9/O0kdRX058ZPCVt4q8G3ccsebm3UyxMBk8DkfT/Cvheynm8KeLYbqHcvlSAODxkZ5FAG/bXU3w/8AGN7pd6D9iaQlD7Z4Neq6brdtcW6vBOrIRnrW98XvAel+PfhpZ+KPD8Y/tGKEMwQ538cg+4P86+cfAUs/9vR2dzI6CNsFCe47UAfQtvcJPHu4x61LG+7BI+X371RswkUYwM5pt/epbx72bAx09KANCSVA2FHNc74xu3g02V4+oFWLS+85w+Mg1zfxCuydKdE6lgKANzQEka2ibPGM1tMNoYjk4rL8PZ+wW46HYM1rSfc4HNAFW2uf3oV+cGtLeJEJ7DoBXNmQNcvGvDKela2nznaUxyKAJWl2sAcgdK5vxowOi3XIBK9a6aQiQHI/OuM8eMRpkke375A60ATeAZRJolruQFlGPrXXFSDkAAVg+DrBbbS7dcEEKDmtbUbtYY8Y+agC1GyhuRz3qzvyB8uK5+0uQzEu2c+9bMT/ALobvwNAD1Yb8Z4pWOUwKx5tSVNQS3yATkitaN90Y4zQBTuLWOZwGFIloqD5VH1qe6kWJNx59qrwXaOeuCOgNAD/ACSpwOO9WYxlevIqPJfkc0y4nWGLBzmgCO4j3AnjNcb4rlm063e8gk2lOtdJNqSBsNjOK84+IuuJNCNMtSHmmYA47UAYFrJqvjvXbWxQFk3YwOgHrXe/FbUxoulWXgzSmCxwgG5Zf4m9DXT+GIdC+GvgB7+8QyeIbmPMAI4GfWvP/Bei3njLxOryB5ri4k3Edc0Aej/s/fDY6vKmrahtFhAR8veRuuK+nNX1C20jTJry6ZY4IVz6fQCqnhPQrbw5odvp9ooVUGXPq3c182/tKfE3z7iTRdMnzDEdrFTwT3NAHmPxt8cy+JtemCyloEY9+Cc/yryV23HNS3MzSOSTnmoKACiiigAooooAK6HwN4juvC/iK11G0cq0bgnFc9RQB+m/gnxBb+KPDFlqlswZZoxvHo3cV89ftK/DGG2j/tvRodschPmxqPun/CuR/Zg+JraDrC6Hqs5Gn3JwCx4Ruxr7C1bTrTWtLms7xFmtZ0wcHsehBoA+K/gp49vbCZvDd3dNHbSZ8vceAfSuV+KGjXfhzxc2pQrsjlfeCvHNbvxm8DJ4O8RSvp11vmhk3gKMFQeRW5pesW/xP8LjSbyGNdXto8Kw6uR0oAl8IeI4dYsYyXxMFG4Z71r6wgmtDt5PrXhazan4N1iS1uYjG8b4OR1Fep6L4ntdVtFKMA+PmBPegDQ05jb2xJOMetcrrVw2p6lHbI29Q2Wx2rS8RavHbWUnllTkcD3qt8MNLe7ikvZgSzOcE9xQB6FpNv5drEAe2KkvHaNSuatRgRxYPp2rD1rULe2tpXkcLt7mgDLjZ5L6RwSGBq9Z3oa5KHhx1FUNCcXEZmVgVbkYqvrm6zmhvFBwrAOB6UAdwreZECF7VyXi1VkuLSLaTucGui065Se0R4zlGGQa5zXWSXX7OLOMc0AdXZgRwg4xgVyfiC7Zro7HJHp6V0d3dLbae5dsBRmvO7a9lv555eNm7j6UAa+i3P2nUvIYnEYya7gkR2+3vivMfC0zweJLnzD8rivQLq6SO3MhwcDnNAHHatcgeL7ONcZwS3Neg2bgRAheK8g0eVtY8Xy3BU7EJAr16xwkAB5HvQBma1KVfA6GsW7uVVRIpOVPFdNfQJK24gE9K4Xxu76dbbkUDJoA7bTZ/Ntkc/NkVW1i5SKCSaRgqqM5Ncx4e8VWh09DO4j4wRmuR8ceLH1aX+y9JUsHO1mHf6UAUNe8Y3U1xJHZHJY7RgZNdH8N/B6mc6/4nYrbxDzNrnlj1qDw9oWl+E7RdS13ZPcsMrG3ODS6p4nuvFkqWNlEbexJwVX+KgA8Q6nP4v14GJWFpG2yFPavp34GfD8+GdPGpXgH2m4jHloRyinv9TWX8EfhbbaXYR6rrVsks8mGgjcZ2j+8R/Kt745fESLwT4faK2dP7SuFKoM8oPXHrQBynx9+L0Og2s+iaHKGvXBWaZD9z/ZFfGurahLe3Uksrl3c5JPepte1WfUb2ae4kZ5JGJJJrIoAKKKKACiiigAooooAKKKKAJLeaS3mSWJirqcgivtH9mr4rDxFYReH9XlzfwriGRjywH8J/pXxVWhoerXei6jDeWEzxTRsGDKcGgD9E/iF4E03xdpN5HLBGl/JHtSfHOR0B9q+GdZ0rVvA/iZ5IRJBdWsuCOnQ96+vPgb8WrHxxpkNjezCPWokAYNx52O4961fiv8ADOx8aWj3EYEOpIhCsAMS+gb396APnObU9B+JOhL9rjih1kLh88EtjqK8h1TTtS8J6iY5FcRk/K3ZhW94x8F634K1pmaOW2lQ7lyMcdq0LLxzZ6vbLp3ii1U8bfNxQBzs+pQahYgiR/PHJXtXqnwxvYDokcasFdCQQeteN+ItPtLTVD/YVwZ4DyMHlag07XtQ0y5DpIcjgqeM0AfR2oXWNwRvyNczqukvqqGKR2CN2FcPafEKMqDcxSK+OdvIrq9C8W2VzCJXuYl5+6zAEUAavh/QbjSohGJd0ecjNbd7YrPbnzF7d6q6f4isb+YQxyrnHUGrNq95q12lnZwsZJG2qT0oA5efV30aYW8KtJngKvOKuavoGtf2OmtlDvHzhT1xXeWvw3v9Lun1DULYTiH5mC/MB+NbWo6ZHr+lta216sVww+6zbcewFAHzjqvjS61Gze2ljMRHBwa0vCTfaLEkgcHmtPxJ4JGjaxcWeoBUuhycHINO02CG2t2VIcMBxjvQA+C28u687A471T8X64YbIxI2HcbePSk1HVXsl5tnbcOPrXF61aavqUZvDbyeSvO4DgCgD0n4fadHDYibHzyDcxPeuxmmEUY2nA7mvF/DHjp9Ltfs92jSKvAI4xVjWfiLvgK2qsMjvQB6jd61b28Z86VB75xXl3xC8TQX4FvbuCFPJHeuMFxq2uTlYBLJnnviuk0DwYroJtVuUjOeUJ5oA5/R01LVpjbWIKx/xN2FdjbQ6T4Rt3e7dLm/IzxyQfaruoajoXhrRnTTCs95JldqnofU1wmnadd6ze7pUeV3OcYoAfcTXuv34eV38pm+VfQV9I/AX4aC5nj1HUIMWUBBG4f61vQe3rU/wj+C8jQ299raCK1Yb1T+Nvb2r6Euriw0DSDLM0drY2yfQADsPegDL8d+J7Twh4audRuWVSiEQp03NjgY9BX5/wDxB8W33ibWZ72+meR3Y43HOBXe/Hr4nS+L9WkitnZNPhJWJM9R6mvE3cu2TQAhOTzSUUUAFFFFABRRRQAUUUUAFFFFABRRRQBo6FrF5omoRXdhM8UqHIKnFfaXwX+OWneKba303XpFttVACCVjhZT7+hr4cqa1uJbWZZYHZHU5BBxQB+lvjPwjpPjDTDaatCHGP3cq/eT6H09q+VPir8Cr3Qnlu9Pja6sOSJEHKj3HarXwb/aCutI8nTPE5e6sRhVkJ+eP8e49q+rdD1zSvEenrcaXdwXdvIvIUgkA9mXtQB+al5pV3ZSH5HGPwNQ2d79nmzcxCZe6tX3r41+DGgeInkmt91jcPz8igpn6dq8G8e/s/a5pNvJc2Yjv7dOS0X3gPXHWgDxk3ehXgCvZtakD7yN1NOsvDsN/k219GnoHNLfeFLq2Zg8ciFTggiqEmjXcLAITz6ZFAGreeHNQ0zZLaXgkbqPKbmpdO8d+ItGl2iZhInQsORWZYrqNnNG5kcKG5Gal8YXov9QSWGPbhQGwOpoA9V8O/tA6raWTWupQvPE4+cg9a3NI+OWmwyLKYYEOckSQ7j+dfPcV4Ej2lOfpVKYhpWIxj2oA9t8WfFHQtauzJLa3DtnPmDrXOW3jjS7G5a4t1uZSekcg4rzyG5jjwDECveuk0rW9Ftoh59gDJnrigDpbv4oQzuuzSEZh2NU9R8a65qtg1pYaZ5EEnXahOahm8Y6TDk2ulxtIBgEqMVA3xCuCFCWcUajstAFK08J6vqDA3CCBT61s2/g/T7AhtUmDhefvYFZFx401W4BECCMnqQOtZVwupX/z3UrkH3oA7K88W6XpUJg0uBSy8DaOPzrjLrUL/VrpnBZQx6A4rS0rwrNdsu2JyDxnFe7/AAw+Cy3UsE9++8H5tgXAUe5oA8k8G+BL7VLuPdE5XqWNfWHwk+HtlY2y6hqGmpHKvESyDOf9rFd54d8JaVoUIS2t0Z/7zjNauq6jaaTYS3moTJDbxDLMxx+H1oAh17WLHQNKmv8AUplhtoVyT3PsB618Y/G34xXni66e0sWNvpcZISNTy3ual+PfxYfxVfNZ2DMmnxHCqD1968JmkMjZNACzTNKxLGoqKKACiiigAooooAKKKcpA6gH60AdhaWVq3w+numt4jchjiUoNw+Yd642iigAooooAKKKKACiiigBVOCMV658FtQvbXW7c213cQktz5cjL/I0UUAfdulyNLp1s8jFnaMEk9+KtUUUAcb400HSbhWmn0yyklKHLtCpJ59cV4P8AEXSrC2ml+z2VvF8o+5GB2oooA8puo0FpLhF6+lZJhi8rPlpnnnFFFAGRPFHl/kXr6VnzxpvzsX8qKKAJGiTYvyL+VULpFBGFA+goooAjVRs6D8qu2qLhflH5UUUAbkKJ8nyr27V0WgQxvcMGjUjHQiiigD6E+A2n2dzNc/aLWCXGMb4w2Pzr3qGGOBAkMaRoP4UUAfpRRQA+vmz9q26uFaCBZ5Vh8sHYHIX8qKKAPki9JL8k1VoooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A nodular enhancing lesion produces moderate mass effect on the frontal horn of the right lateral ventricle in this T1-weighted image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2992=[""].join("\n");
var outline_f2_59_2992=null;
var title_f2_59_2993="Breech extraction2";
var content_f2_59_2993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78129&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Delivery of the arms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gentle traction on the pelvis. Note that traction is not applied above the pelvis. Continuation of traction, with rotation as the scapulae becomes visible, sweeping the posterior and then anterior arm free in the process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART, Obstetrics &amp; Gynecology. Copyright &copy;2009 Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2993=[""].join("\n");
var outline_f2_59_2993=null;
var title_f2_59_2994="JSGE classification of early endoluminal cancers";
var content_f2_59_2994=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Japanese Society for Gastroenterological Endoscopy classification of early endoluminal cancers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. Gastric Cancer 1998; 1:10, with kind permission from Springer Science + Business Media B.V.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2994=[""].join("\n");
var outline_f2_59_2994=null;
var title_f2_59_2995="Urticaria annular lesions 2";
var content_f2_59_2995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Urticaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple mildly erythematous and edematous plaques are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2995=[""].join("\n");
var outline_f2_59_2995=null;
var title_f2_59_2996="Fistula closure clip endos";
var content_f2_59_2996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Treatment of ileocolonic anastomosis fistula with endoclips",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient developed ischemic colitis following an aspirin overdose and required a subtotal colectomy and temporary ileostomy. Following creation of an ileal-sigmoid anastomosis he developed a large abscess and was found the have a large post-operative fistula at the anastomotic site as shown above. In addition to percutaneous abscess drainage, twelve Resolution clips were placed during colonoscopy to close the defect. Subsequently, the abscess drainage subsided and the patient was able to tolerate refeeding within two weeks without the subsequent need for reoperation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Cohen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2996=[""].join("\n");
var outline_f2_59_2996=null;
var title_f2_59_2997="Incidence of primary brain tumors";
var content_f2_59_2997=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Incidence of primary brain tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Dominique Michaud, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2997/contributors\">",
"     David Schiff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Tracy Batchelor, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2997/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/59/2997/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary brain tumors are a diverse group of neoplasms arising from different cells of the central nervous system (CNS). Although uncommon, there is evidence that the incidence of these tumors has been rising for as much as fifty years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link&amp;anchor=H7347120#H7347120\">",
"     \"Classification of gliomas\", section on 'Histopathologic and molecular classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of primary malignant and benign brain tumors will be reviewed here. Risk factors for the development of brain tumors as well as the incidence of brain metastases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=see_link\">",
"     \"Risk factors for brain tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES OF DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Central Brain Tumor Registry of the United States (CBTRUS) includes both benign and malignant lesions in its data collection. The CBTRUS was established in 1992 and compiles information from twelve state cancer registries [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/1\">",
"     1",
"    </a>",
"    ]. Earlier data from the SEER program and other US cancer registries were limited to malignant brain tumors; however, as of 2004, data on nonmalignant brain tumors have been systematically collected by US cancer registries after the passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inclusion of benign lesions is important to properly evaluate differences in etiology and to assess the potential impact of intervention studies. Benign lesions often produce the same neurologic symptoms as malignant tumors and distinguishing between benign and malignant based upon clinical grounds can be difficult. In addition, both benign and malignant lesions are frequently treated similarly with either surgical intervention or radiation therapy, and many malignant brain tumors probably originate from benign precursors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=see_link&amp;anchor=H7347120#H7347120\">",
"     \"Classification of gliomas\", section on 'Histopathologic and molecular classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US incidence rate for primary brain and nervous system tumors in adults (aged 20 years or older) was estimated to be 24.6 per 100,000 persons (data from 46 cancer registries, 2004 to 2007) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately one-third of tumors were malignant and the remainder were benign or borderline malignant. The incidence rate for children (aged 0 to 19 years) was much lower (48.6 per 1,000,000 children), although 65 percent were malignant compared with 33 percent in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although brain tumors account for only 2 percent of all cancers, these neoplasms result in a disproportionate share of cancer morbidity and mortality. The annual age-adjusted mortality rate for malignant brain cancer in the United States (1997 to 2001) was 4.6 per 100,000 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/3\">",
"     3",
"    </a>",
"    ]. Including all ages and all races, the approximate five-year survival rate for malignant brain tumors was 33 percent. The five-year survival rates for the most common histologic subtypes, anaplastic astrocytoma and glioblastoma, are 30 percent and 3 percent, respectively.",
"   </p>",
"   <p>",
"    For all histologic types, pediatric and young adult populations have a better survival than do older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, for all primary malignant brain tumors combined, the five year survival rate among children under age 14 is 62 percent, compared to 5 percent in adults 65 years of age and older [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall survival in patients with malignant brain tumors has not improved significantly over the last fifty years. However, survival rates vary according to age and histologic type. As an example, there were modest gains in survival between 1975 and 1995 for those younger than 65, but not older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/4\">",
"     4",
"    </a>",
"    ]. Although little progress has been made in survival from glioblastoma in the last thirty years, five-year survival rates for medulloblastoma increased by 20 percent from the 1970s to the 1980s, although data suggest a leveling off of survival rates [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, young age, high performance status, and lower pathologic grade are favorable prognostic factors for primary brain tumors. Less significant predictors of favorable prognosis include long duration of symptoms, absence of mental changes at time of diagnosis, cerebellar location of tumor, small preoperative tumor size, and completeness of surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a slight male predominance in the incidence of malignant brain tumors (8.0 versus 5.5 per 100,000 person-years for women in the years 1997 to 2001) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/3\">",
"     3",
"    </a>",
"    ]. However, when both malignant and benign tumor types are examined, males accounted for less than one-half of all cases (44 versus 56 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/1\">",
"     1",
"    </a>",
"    ]. This difference is primarily explained by the higher incidence of meningiomas in women (7.8 versus 3.5 per 100,000 person-years in men) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whites have a higher incidence of malignant brain tumors compared to blacks for both genders (8.8 versus 4.9 per 100,000 person-years in men, and 6.1 versus 3.2 per 100,000 person-years in women) (",
"    <a class=\"graphic graphic_figure graphicRef51025 \" href=\"UTD.htm?37/53/38750\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/3\">",
"     3",
"    </a>",
"    ]. In general, malignant brain tumors are less common among Asian Americans and Native Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/7\">",
"     7",
"    </a>",
"    ], while the incidence of malignant brain tumors in Hispanics is intermediate between that in whites or African Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, incidence rates for meningiomas do not vary substantially by race (6.9 per 100,000 person-years in non-Hispanic blacks, 6.1 per 100,000 person-years in non-Hispanic whites, and 6.5 per 100,000 person-years in Hispanics) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of brain tumors varies with age and histology (",
"    <a class=\"graphic graphic_figure graphicRef72275 \" href=\"UTD.htm?28/44/29391\">",
"     figure 2",
"    </a>",
"    ). Data compiled from several tumor registries suggest a peak incidence of all primary brain tumors around age 50, although autopsy series suggest that incidence rises continuously with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/9\">",
"     9",
"    </a>",
"    ]. Most intracranial tumors occur in people older than 45 years of age. Glioblastoma rarely occurs before the age of 15 but dramatically increases after the age of 45. In contrast, medulloblastoma, and other embryonal tumors are uncommon after the age of 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, gliomas (principally astrocytoma) account for approximately 50 percent and meningioma 25 to 30 percent of symptomatic primary brain tumors (",
"    <a class=\"graphic graphic_table graphicRef81566 \" href=\"UTD.htm?6/44/6862\">",
"     table 1",
"    </a>",
"    ). The incidence of meningioma increases to 40 percent when neuroimaging studies are included because of the large number of asymptomatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/9\">",
"     9",
"    </a>",
"    ]. Pituitary tumors account for 10 to 20 percent, primary central nervous system lymphoma for 3 to 5 percent, and craniopharyngioma for 1 to 3 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children under the age of 15 years, brain tumors are the most common solid malignancy and the second leading cause of cancer death after leukemia. Brain cancer rates are approximately 2 to 2.5 per 100,000 per year and the male-to-female ratio is approximately 1.2:1.",
"   </p>",
"   <p>",
"    The different histologic subtypes seen in children and their relative frequency are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef67876 \" href=\"UTD.htm?3/35/3644\">",
"     table 2",
"    </a>",
"    ). The most common include low-grade astrocytomas, malignant gliomas, and medulloblastomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Temporal trends",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have documented rising incidence rates for brain tumors in several industrialized countries; this increase seems to be confined mainly to the elderly population, with no clear ethnic, gender or geographic differences. The incidence in whites rose 80 percent from 1950 to 1994 and 18 percent from 1973 to 1994 (",
"    <a class=\"graphic graphic_figure graphicRef64211 \" href=\"UTD.htm?0/24/399\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/3,11,12\">",
"     3,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increases observed in the United States were present in all age strata and racial groups, similar to findings in other parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/13\">",
"     13",
"    </a>",
"    ]. There is limited epidemiological evidence from a longitudinally studied population in Rochester, Minnesota suggesting that a rise in brain tumor mortality may have been evident since the 1940s [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise etiology of this increase in brain tumor incidence remains unclear. There is agreement that at least part of this increase is the result of more complete case ascertainment with improved diagnostic technology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/9,15\">",
"     9,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The introduction of noninvasive diagnostic technology including computerized tomography (CT) in the 1970s and magnetic resonance imaging (MRI) in the 1980s.",
"     </li>",
"     <li>",
"      The improvement in health care access for the elderly population improved and an increase in the availability of neurologists; the number of neurologists in the United States increased 3.6-fold from 1970 to 1987 [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, improved diagnostic capability cannot fully account for the magnitude of the observed increase in brain tumor incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2997/abstract/7,15\">",
"     7,15",
"    </a>",
"    ]. These data, in conjunction with the evidence suggesting the increase may have been occurring for many decades, leave open the possibility that an environmental exposure may account for part of the increasing incidence of brain tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=see_link\">",
"     \"Risk factors for brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     International trends and migrant studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing incidence rates of brain tumors have been observed in many other countries of the world over the last thirty years. The highest incidence rates are noted in industrialized nations such as the United States, Canada, Australia, and the United Kingdom, while developing nations have lower rates. In general, the brain cancer incidence appears to be associated with the level of economic development; differences in the availability of diagnostic methodology (CT, MRI, neurosurgical technology) may account for some of the observed disparities.",
"   </p>",
"   <p>",
"    Despite sparse data from developing countries, it appears that most migrants acquire the brain cancer incidence rates of their host country. For most migrant studies, the host country had elevated incidence rates compared to the country of origin, with migrants developing increases in brain cancer incidence and mortality. This observation suggests that environmental factors may influence the development of brain cancer. However, these studies were complicated by disparities in case ascertainment in the countries under study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Primary central nervous system lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There was an overall increase in the incidence of primary central nervous system lymphoma from the 1960s to the 1990s, which has been attributed at least in part to an increased frequency of these tumors in immunocompromised populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    Benign tumors can produce substantial morbidity and can occasionally be fatal. As of 2004, data on the benign tumors are being collected systematically by all cancer registries. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Sources of data'",
"    </a>",
"    above.) The most common malignant brain tumors, glioblastomas, are rapidly fatal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality data on individuals with brain tumors indicate that younger patients have a significantly better prognosis compared to older individuals. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of brain tumors varies with age and histology. Gliomas and meningiomas are most common tumors in adults, while there are a number of less common tumor types that are seen almost exclusively in children (",
"      <a class=\"graphic graphic_table graphicRef67876 \" href=\"UTD.htm?3/35/3644\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall incidence of brain tumors has been rising. This is most likely due to more frequent diagnosis with improved imaging modalities, but there is a possibility that environmental factors may be contributing to a true increase in incidence as well. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Temporal trends'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cbtrus.org/reports/reports.html (Accessed on October 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/2\">",
"      Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda, MD seer.cancer.gov/csr/1975_2001 (Accessed on April 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/4\">",
"      Wrensch M, Minn Y, Chew T, et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002; 4:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/5\">",
"      Davis FG, Freels S, Grutsch J, et al. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/6\">",
"      Wen PY, Fine HA, Black PM, et al. High-grade astrocytomas. Neurol Clin 1995; 13:875.",
"     </a>",
"    </li>",
"    <li>",
"     Preston-Martin S, Mack WJ. Neoplasms of the nervous system. In: Cancer Epidemiology and Prevention, 2nd, Shottenfeld D, Fraumeni JF (Eds), Oxford University Press, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/8\">",
"      Chakrabarti I, Cockburn M, Cozen W, et al. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 2005; 104:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/9\">",
"      Radhakrishnan K, Mokri B, Parisi JE, et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol 1995; 37:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/10\">",
"      Giordana MT, Schiffer P, Lanotte M, et al. Epidemiology of adult medulloblastoma. Int J Cancer 1999; 80:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/11\">",
"      Davis DL, Ahlbom A, Hoel D, Percy C. Is brain cancer mortality increasing in industrial countries? Am J Ind Med 1991; 19:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/12\">",
"      Modan B, Wagener DK, Feldman JJ, et al. Increased mortality from brain tumors: a combined outcome of diagnostic technology and change of attitude toward the elderly. Am J Epidemiol 1992; 135:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/13\">",
"      Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006; 8:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/14\">",
"      KURLAND LT. The frequency of intracranial and intraspinal neoplasms in the resident population of Rochester, Minnesota. J Neurosurg 1958; 15:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2997/abstract/15\">",
"      Polednak AP. Interpretation of secular increases in incidence rates for primary brain cancer in Connecticut adults, 1965-1988. Neuroepidemiology 1996; 15:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5216 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2997=[""].join("\n");
var outline_f2_59_2997=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES OF DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Temporal trends",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - International trends and migrant studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5216\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5216|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/53/38750\" title=\"figure 1\">",
"      Brain cancer by race and age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/44/29391\" title=\"figure 2\">",
"      Incidence rates of primary brain tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/24/399\" title=\"figure 3\">",
"      Rising incidence brain cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5216|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/44/6862\" title=\"table 1\">",
"      CBTRUS incidence of primary CNS tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/35/3644\" title=\"table 2\">",
"      CBTRUS ped hist dist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_59_2998="Exercise in the treatment and prevention of hypertension";
var content_f2_59_2998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise in the treatment and prevention of hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/2998/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2998/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/2998/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2998/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/2998/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/2998/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/59/2998/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term aerobic exercise regimens (in most studies) have had a beneficial effect on the systemic blood pressure (BP) and therefore may reduce the incidence of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. During aerobic exercise, there is an appropriate elevation in BP, primarily systolic. However, some subjects have an exaggerated increase in BP during exercise, which may be an adverse prognostic sign. In addition to aerobic exercise, resistance training has been shown to reduce BP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both aerobic exercise and resistance training lower resting blood pressure (BP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6860911\">",
"    <span class=\"h2\">",
"     Aerobic exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular aerobic exercise can lower the BP by as much as 5 to 15 mmHg in patients with essential hypertension, although the effect is not as pronounced among older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/8\">",
"     8",
"    </a>",
"    ]. In meta-analyses of randomized, controlled trials, the mean reduction in systolic and diastolic BP was 4 to 6 and 3 mmHg, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ]. Patients with resistant hypertension may also benefit from aerobic exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Swimming training also can have a beneficial effect [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/12\">",
"     12",
"    </a>",
"    ]. It may be particularly useful in patients with orthopedic problems or, because of the warm, humid environment, those with bronchospasm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar fall in BP has been demonstrated in subjects with borderline hypertension, with the BP often being lowered into the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/13\">",
"     13",
"    </a>",
"    ]. In comparison, the incidence of hypertension is increased in individuals with a low level of fitness [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BP response to exercise is dependent upon continuation of the exercise program, as abstention from exercise is associated with a return of the BP toward the pre-exercise level [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition to voluntary exercise, spontaneous physical activity (fidgeting) is another potentially important source (100 to 800",
"    <span class=\"nowrap\">",
"     kcal/day)",
"    </span>",
"    of energy expenditure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With few exceptions, most studies have shown a persistent fall in BP that is more dependent upon the intensity of exercise than on its frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/10\">",
"     10",
"    </a>",
"    ]. In a study of 207 untreated hypertensive patients, for example, those who exercised for eight weeks at an intensity of 50 percent of estimated maximal oxygen consumption only two times a week for a total of 60 minutes had almost as much fall in BP (about",
"    <span class=\"nowrap\">",
"     12/6",
"    </span>",
"    mmHg) as those who exercised more than five times a week for a total of more than 120 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its antihypertensive effect, regular aerobic exercise also provides other cardiovascular benefits. These include a fall in total cholesterol, an elevation in HDL-cholesterol, a reduction in weight, and a decline in overall cardiovascular mortality (",
"    <a class=\"graphic graphic_figure graphicRef82815 \" href=\"UTD.htm?22/1/22558\">",
"     figure 1",
"    </a>",
"    ). The effects of both duration and intensity of exercise on primary and secondary prevention of cardiovascular disease are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6860951\">",
"    <span class=\"h2\">",
"     Resistance training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance (strength) training with either dynamic (in which joint angles and muscle lengths change) or pure isometric (in which they do not) exercise also reduces resting BP [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/7,10,17\">",
"     7,10,17",
"    </a>",
"    ]. A meta-analysis of 28 trials that enrolled 1012 participants found that resting BP significantly decreased by",
"    <span class=\"nowrap\">",
"     4/4",
"    </span>",
"    mmHg with moderate-intensity resistance training [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/7\">",
"     7",
"    </a>",
"    ]. The effect of resistance training was slightly larger with isometric (as compared with dynamic) resistance and in normotensive (as compared with hypertensive) individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors responsible for the potential antihypertensive effect of long-term aerobic exercise are incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/18\">",
"     18",
"    </a>",
"    ], although both a reduction in sympathetic activity and an improvement in endothelial function have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/3,4,19-21\">",
"     3,4,19-21",
"    </a>",
"    ]. As an example, a randomized trial of 28 patients with a recent myocardial infarction showed that exercise training improved baroreceptor sensitivity and reduced muscle sympathetic nerve activity [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/19\">",
"     19",
"    </a>",
"    ]. Another study that performed muscle biopsies on patients with hypertension before and after an exercise program documented decreased levels of the vasoconstrictor thromboxane and increased levels of the vasodilator prostacyclin [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/20\">",
"     20",
"    </a>",
"    ]. Although the forgoing studies minimized concurrent weight loss, which would confound their results, patients who exercise may derive additional advantages through the effects of exercise on weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     BETA-BLOCKERS AND EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to perform exercise may be adversely effected by antihypertensive medications. In particular, beta-blockers (particularly those that are nonselective) can significantly diminish exercise performance. There is, however, a training effect, and maintenance of performance levels has been observed in patients treated with beta-blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/23\">",
"     23",
"    </a>",
"    ]. Other classes of antihypertensive drugs have no detrimental effect on the ability to exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXAGGERATED EXERCISE-INDUCED HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strength training and pure isometric exercise, such as weight lifting, can",
"    <strong>",
"     acutely",
"    </strong>",
"    raise the blood pressure (BP) to as high as 230 to",
"    <span class=\"nowrap\">",
"     330/170",
"    </span>",
"    to 250 mmHg in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/24\">",
"     24",
"    </a>",
"    ]. Reflex-mediated increased cardiac output and elevated vascular resistance (due in part to mechanical compression in the exercising muscles) contribute to this hypertensive response. The marked increase in BP with intense isometric exercise can precipitate intraocular bleeding or retinal detachment, particularly in patients with severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy, in whom such exercise is discouraged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link&amp;anchor=H8492005#H8492005\">",
"     \"Effects of exercise in diabetes mellitus in adults\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aerobic exercise, on the other hand, is associated with an increase in cardiac output acutely but a reduction in vascular resistance due to vasodilatation in the exercising muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/19,20,24\">",
"     19,20,24",
"    </a>",
"    ]. As a result, the systolic pressure rises modestly, usually with no change or a slight reduction in diastolic pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients have a marked (exaggerated) rise in systolic pressure with aerobic exercise, frequently defined as a peak systolic pressure during exercise of 200 mmHg or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Proposed pathogenetic factors include increased sympathetic tone during the stress of exercise and a decrease in aortic distensibility, which exacerbates the elevation in systolic pressure induced by the rise in cardiac output.",
"   </p>",
"   <p>",
"    An exaggerated exercise-induced risk in systolic pressure is not always reproduced on subsequent exercise tests. This was illustrated in a report of 117 such patients who underwent two to seven exercise tests [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/28\">",
"     28",
"    </a>",
"    ]. An exaggerated response (defined as a BP at peak exercise that exceeded 200 mmHg systolic and 100 mmHg diastolic) occurred in at least two-thirds of tests in only 18 (15 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exercise-induced hypertension and cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;An exaggerated elevation in systolic pressure during or after exercise may be prognostically important. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have exaggerated transient elevations in BP during exercise or mental stress (particularly at work) may be particularly prone to the development of left ventricular hypertrophy (LVH) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cardiovascular mortality is increased among individuals with severe BP elevations in response to exercise. In a prospective report of 2000 apparently healthy men aged 40 to 59 who underwent a six minute standardized bicycle exercise test, the cardiovascular death rate at 16 years was increased more than two-fold in subjects with a postexercise systolic BP &gt;200 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normotensive individuals with an exaggerated BP response to exercise may be at increased risk for subsequent hypertension. In a report from the Framingham Heart Study, an exaggerated diastolic (not systolic) response, defined as an age-adjusted value &gt;95th percentile, was predictive of subsequent hypertension in men and women, and an increased systolic response during recovery was predictive in men [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/30\">",
"       30",
"      </a>",
"      ]. Similar results have been noted among 6557 normotensive Japanese men [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, exercise-induced hypertension may not be an adverse prognostic indicator in patients with suspected or known coronary disease. In one report of over 3000 such patients referred for exercise testing, those with exercise-induced hypertension (defined as a peak systolic BP &ge;210 mmHg in men and &ge;190 mmHg in women) were less likely to have perfusion abnormalities on a thallium scan or to have extensive abnormalities, and there was no increase in mortality at six year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent report from the same group noted a worse prognosis in patients with delayed decline in systolic BP after exercise, defined as a ratio of systolic BP at three minutes to systolic BP at one minute of recovery greater than one [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/33\">",
"     33",
"    </a>",
"    ]. This finding was associated with a greater likelihood of severe coronary artery disease, ie, left main, three-vessel, or two-vessel disease with proximal left anterior descending artery involvement (34 versus 17 percent, p = 0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/2998/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/56/40835?source=see_link\">",
"       \"Patient information: Controlling your blood pressure through lifestyle (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=see_link\">",
"       \"Patient information: High blood pressure, diet, and weight (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular aerobic exercise and resistance training are usually accompanied by a fall in blood pressure (BP), which can be beneficial in the treatment of hypertension. In addition, regular exercise can likely delay, if not stop, the development of hypertension. All individuals should be advised to gradually increase their levels of physical activity.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/1\">",
"      Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/2\">",
"      Blair SN, Goodyear NN, Gibbons LW, Cooper KH. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 1984; 252:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/3\">",
"      Duncan JJ, Farr JE, Upton SJ, et al. The effects of aerobic exercise on plasma catecholamines and blood pressure in patients with mild essential hypertension. JAMA 1985; 254:2609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/4\">",
"      Nelson L, Jennings GL, Esler MD, Korner PI. Effect of changing levels of physical activity on blood-pressure and haemodynamics in essential hypertension. Lancet 1986; 2:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/5\">",
"      Kelemen MH, Effron MB, Valenti SA, Stewart KJ. Exercise training combined with antihypertensive drug therapy. Effects on lipids, blood pressure, and left ventricular mass. JAMA 1990; 263:2766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/6\">",
"      Nakanishi N, Suzuki K. Daily life activity and the risk of developing hypertension in middle-aged Japanese men. Arch Intern Med 2005; 165:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/7\">",
"      Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a meta-analysis of randomized, controlled trials. Hypertension 2011; 58:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/8\">",
"      Stewart KJ, Bacher AC, Turner KL, et al. Effect of exercise on blood pressure in older persons: a randomized controlled trial. Arch Intern Med 2005; 165:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/9\">",
"      Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens 2006; 24:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/10\">",
"      Cornelissen VA, Buys R, Smart NA. Endurance exercise beneficially affects ambulatory blood pressure: a systematic review and meta-analysis. J Hypertens 2013; 31:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/11\">",
"      Dimeo F, Pagonas N, Seibert F, et al. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension 2012; 60:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/12\">",
"      Tanaka H, Bassett DR Jr, Howley ET, et al. Swimming training lowers the resting blood pressure in individuals with hypertension. J Hypertens 1997; 15:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/13\">",
"      Somers VK, Conway J, Johnston J, Sleight P. Effects of endurance training on baroreflex sensitivity and blood pressure in borderline hypertension. Lancet 1991; 337:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/14\">",
"      Barengo NC, Hu G, Kastarinen M, et al. Low physical activity as a predictor for antihypertensive drug treatment in 25-64-year-old populations in eastern and south-western Finland. J Hypertens 2005; 23:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/15\">",
"      Ravussin E, Lillioja S, Anderson TE, et al. Determinants of 24-hour energy expenditure in man. Methods and results using a respiratory chamber. J Clin Invest 1986; 78:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/16\">",
"      Ishikawa-Takata K, Ohta T, Tanaka H. How much exercise is required to reduce blood pressure in essential hypertensives: a dose-response study. Am J Hypertens 2003; 16:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/17\">",
"      Cornelissen VA, Fagard RH. Effect of resistance training on resting blood pressure: a meta-analysis of randomized controlled trials. J Hypertens 2005; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/18\">",
"      Arakawa K. Antihypertensive mechanism of exercise. J Hypertens 1993; 11:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/19\">",
"      Martinez DG, Nicolau JC, Lage RL, et al. Effects of long-term exercise training on autonomic control in myocardial infarction patients. Hypertension 2011; 58:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/20\">",
"      Hansen AH, Nyberg M, Bangsbo J, et al. Exercise training alters the balance between vasoactive compounds in skeletal muscle of individuals with essential hypertension. Hypertension 2011; 58:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/21\">",
"      Goto C, Higashi Y, Kimura M, et al. Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation 2003; 108:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/22\">",
"      Thorogood A, Mottillo S, Shimony A, et al. Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med 2011; 124:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/23\">",
"      Fahrenbach MC, Yurgalevitch SM, Zmuda JM, Thompson PD. Effect of doxazosin or atenolol on exercise performance in physically active, hypertensive men. Am J Cardiol 1995; 75:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/24\">",
"      Morales MC, Coplan NL, Zabetakis P, Gleim GW. Hypertension: the acute and chronic response to exercise. Am Heart J 1991; 122:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/25\">",
"      Mundal R, Kjeldsen SE, Sandvik L, et al. Exercise blood pressure predicts cardiovascular mortality in middle-aged men. Hypertension 1994; 24:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/26\">",
"      Luijendijk P, Bouma BJ, Vriend JW, et al. Usefulness of exercise-induced hypertension as predictor of chronic hypertension in adults after operative therapy for aortic isthmic coarctation in childhood. Am J Cardiol 2011; 108:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/27\">",
"      Goel R, Majeed F, Vogel R, et al. Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease in a marathon runner. Am J Cardiol 2007; 99:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/28\">",
"      Sharabi Y, Almer Z, Hanin A, et al. Reproducibility of exaggerated blood pressure response to exercise in healthy patients. Am Heart J 2001; 141:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/29\">",
"      Gottdiener JS, Brown J, Zoltick J, Fletcher RD. Left ventricular hypertrophy in men with normal blood pressure: relation to exaggerated blood pressure response to exercise. Ann Intern Med 1990; 112:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/30\">",
"      Singh JP, Larson MG, Manolio TA, et al. Blood pressure response during treadmill testing as a risk factor for new-onset hypertension. The Framingham heart study. Circulation 1999; 99:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/31\">",
"      Tsumura K, Hayashi T, Hamada C, et al. Blood pressure response after two-step exercise as a powerful predictor of hypertension: the Osaka Health Survey. J Hypertens 2002; 20:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/32\">",
"      Campbell L, Marwick TH, Pashkow FJ, et al. Usefulness of an exaggerated systolic blood pressure response to exercise in predicting myocardial perfusion defects in known or suspected coronary artery disease. Am J Cardiol 1999; 84:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/2998/abstract/33\">",
"      McHam SA, Marwick TH, Pashkow FJ, Lauer MS. Delayed systolic blood pressure recovery after graded exercise: an independent correlate of angiographic coronary disease. J Am Coll Cardiol 1999; 34:754.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3828 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-BD9846CABD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2998=[""].join("\n");
var outline_f2_59_2998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6860911\">",
"      Aerobic exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6860951\">",
"      Resistance training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BETA-BLOCKERS AND EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXAGGERATED EXERCISE-INDUCED HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exercise-induced hypertension and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3828\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3828|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/1/22558\" title=\"figure 1\">",
"      Exercise intensity and duration and reduction in mortality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=related_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/56/40835?source=related_link\">",
"      Patient information: Controlling your blood pressure through lifestyle (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/8/9347?source=related_link\">",
"      Patient information: High blood pressure, diet, and weight (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_59_2999="Chickenpox oral 2";
var content_f2_59_2999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83137%7EDERM%2F83136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83137%7EDERM%2F83136&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Oral manifestations of varicella (chickenpox)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gingival vesicle in a patient with chickenpox.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral manifestation of varicella (chickenpox)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_2999=[""].join("\n");
var outline_f2_59_2999=null;
var title_f2_59_3000="Cardiac rehabilitation in patients with heart failure";
var content_f2_59_3000=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac rehabilitation in patients with heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3000/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3000/contributors\">",
"     Ileana L Pi&ntilde;a, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3000/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3000/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3000/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3000/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/59/3000/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heart failure (HF) often have limited exercise capacity because of dyspnea and fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/1\">",
"     1",
"    </a>",
"    ]. It was previously thought that this exercise limitation was due entirely to cardiac dysfunction, and that treatment with inotropes and vasodilators, such as angiotensin converting enzyme inhibitors and the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    and nitrates, would improve exercise capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although these drugs can improve the cardiac output and, with certain vasodilators, patient survival, they may not acutely improve exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Thus, factors in addition to the low cardiac output and reduced skeletal muscle blood flow must contribute to poor exercise tolerance and fatigue.",
"   </p>",
"   <p>",
"    In the 1970s, exercise training of HF patients was discouraged due to concerns of worsening symptoms and detriment to the disease process itself. Early observations in the 1980s documented improvements in exercise function for patients with HF with a low rate of complications.",
"   </p>",
"   <p>",
"    These observations were followed by a series of studies that demonstrated that significant biochemical and functional abnormalities in skeletal muscle are present in patients with HF and play a large role in the exercise intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/1\">",
"     1",
"    </a>",
"    ]. Inactivity is in part responsible, leading to muscle atrophy. In addition, skeletal muscle utilizes high-energy phosphates in an inefficient manner; as a result, lactic acid accumulates at a more rapid rate than in normal controls, contributing to muscle fatigue and limited exercise capacity. Skeletal muscle dysfunction can also involve the respiratory muscles, which may contribute to fatigue and dyspnea on exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/6\">",
"     6",
"    </a>",
"    ]. These biochemical and functional abnormalities, when added to deconditioning, can result in even greater impact on physical function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=see_link\">",
"     \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of skeletal muscle dysfunction provides part of the rationale for the use of cardiac rehabilitation in patients with HF. This topic will review the evidence demonstrating the benefit of cardiac rehabilitation in patients with mild to moderate (NYHA class II to III) heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and make recommendations about an exercise prescription. Measurement of peak oxygen uptake (peak VO2) to assess exercise capacity and prognosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EFFECTS OF EXERCISE IN HEART FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the studies on exercise in heart failure have included patients with low ejection fraction. However, as the number of patients with preserved systolic function heart failure increases, it is important to remember that these patients can be as limited in their exercise capacity as those with low EF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/7\">",
"     7",
"    </a>",
"    ]. Exercise training in compensated heart failure has the following clinical benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enhanced peak VO2, possibly peak cardiac output due to a higher workload achieved, and leg blood flow during exercise. These changes may be related to an improvement in diastolic function as manifested by an increase in the peak early diastolic filling rate of the left ventricle at rest and during exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improved muscle energetics so that oxygen utilization becomes more efficient, allowing a similar amount of work to be performed at a lower heart rate, rate-pressure product, and minute ventilation (indicating improved gas exchange). The lower rate-pressure product may permit patients with coronary disease to perform their daily tasks with fewer symptoms and less disability.",
"     </li>",
"     <li>",
"      Improvement in symptoms such as dyspnea and fatigue, especially if contributed to by deconditioning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there are a number of pathophysiologic changes that are of benefit:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced sympathetic tone and increased vagal tone at rest, thereby restoring autonomic cardiovascular control towards normal; enhanced arterial baroreceptor sensitivity may contribute to this reduction [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. To the degree that these changes reduce systemic vascular resistance and cardiac afterload, they may lead to an improvement in cardiac performance.",
"     </li>",
"     <li>",
"      Reduced neurohumoral activity with decreased resting levels of angiotensin, aldosterone, vasopressin and natriuretic peptide [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"       \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Improvement in endothelial function as evidenced by increased basal endothelial nitric oxide formation and acetylcholine-mediated endothelium-dependent vasodilation of the skeletal muscle blood vessels, possibly leading to an increase in exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Dietary supplementation with L-arginine, which also increases nitric oxide levels, improves endothelial function in patients with heart failure to a similar extent as exercise; both interventions together have additive effects [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/15\">",
"       15",
"      </a>",
"      ]. Aerobic interval training improves flow mediated vasodilation more than moderate continuous training [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction in plasma levels of proinflammatory cytokines, including tumor necrosis factor alpha (TNFa) and interleukin-6 and their soluble receptors, and apoptotic mediators, such as Fas and Fas ligand [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=see_link&amp;anchor=H5#H5\">",
"       \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\", section on 'Cytokines'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No ventilatory, hemodynamic, autonomic, or clinical factor at baseline predicts the outcome with exercise training in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/18\">",
"     18",
"    </a>",
"    ]. An exception may occur in patients with ischemic cardiomyopathy and hibernating myocardium as evidenced by a positive response to low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    . The presence of hibernating myocardium is predictive of an increase in functional capacity and fewer cardiac events during follow-up after moderate exercise training [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/19\">",
"     19",
"    </a>",
"    ]. It is also predictive of an exercise-induced improvement in the contractile response of dysfunctional myocardium to low-dose dobutamine, a finding which correlates with an increase in collateral flow [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effect on hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise training improves measures of left ventricular function and hemodynamics. The magnitude of these effects was illustrated in a meta-analysis of randomized controlled trials of exercise training in chronic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/21\">",
"     21",
"    </a>",
"    ]. Aerobic training was associated with significant improvements in left ventricular ejection fraction (weighted mean difference 2.6 percent), and end-diastolic and end-systolic volumes (weighted mean difference -11.5 mL and -12.9 mL respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Part of the benefit may be mediated by a reduction in total peripheral resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/22\">",
"     22",
"    </a>",
"    ]. Exercise training also reduces plasma brain natriuretic peptide values in patients with HF, another marker of improved hemodynamics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link&amp;anchor=H27657875#H27657875\">",
"     \"Natriuretic peptide measurement in heart failure\", section on 'BNP or NT-proBNP as guide to therapy of HF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of exercise training may be important. In a randomized trial of 27 patients with stable, postinfarction HF who received optimal medical therapy, aerobic interval training at high intensity (at 95 percent of peak heart rate) reversed LV remodeling and improved LV relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/16\">",
"     16",
"    </a>",
"    ]. These benefits were not seen with moderate continuous training (at 70 percent of peak heart rate). In addition, high-intensity training was associated with a greater increase in peak VO2.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect on functional capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous cardiac rehabilitation studies have demonstrated the safety and efficacy of exercise training in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/17,18,21-31\">",
"     17,18,21-31",
"    </a>",
"    ]. These trials have shown that cardiac rehabilitation can produce improvement in maximal exercise tolerance, as measured by an increase in exercise time, peak oxygen uptake (VO2 peak), or NYHA functional class after one to six months of exercise training. In various meta-analyses, exercise training increased the VO2max by about 2.0",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/21,32\">",
"     21,32",
"    </a>",
"    ] or by 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/33\">",
"     33",
"    </a>",
"    ]. An increase in aerobic metabolism after training means that patients may be able to participate in their routine daily activities more easily and comfortably. These trials, however, have been single-center, included small number of patients subject to selection bias, and reported short-term follow-up. None of these small trials were powered to examine mortality and morbidity.",
"   </p>",
"   <p>",
"    In the HF ACTION trial, 2331 patients with reduced left ventricular ejection fraction (LVEF &le;35 percent) and NYHA class II-IV HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) were randomly assigned to a formal exercise program versus a control program [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/34\">",
"     34",
"    </a>",
"    ]. The peak improvement in peak VO2 was modest, though statistically significant (0.6 versus 0.2",
"    <span class=\"nowrap\">",
"     ml/min/kg",
"    </span>",
"    in controls) both at 3 and 12 months, as was the improvement in six-minute walk distance at three months. The six-minute walk improvement at three months was attenuated at 12 months. However, adherence was less than predicted and may have affected the improvement in peak VO2.",
"   </p>",
"   <p>",
"    Aerobic plus strength training was not more effective than aerobic training alone in terms of VO2max [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/33\">",
"     33",
"    </a>",
"    ]. However, there is evidence that the benefit of aerobic exercise on left ventricular volumes may be diminished or lost with the addition of strength training [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/21\">",
"     21",
"    </a>",
"    ]. High-intensity aerobic interval training produced a greater improvement in VO2max than moderate continuous training (45 percent versus 14 percent increase) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients with heart failure infrequently exert themselves to maximal capacity during routine activities of daily living. Most activities occur below the anaerobic threshold. Thus, generally applicable findings come from a study of four to six months of constant work load training involving three to five hours per week of biking, walking, and jogging [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/35\">",
"     35",
"    </a>",
"    ]. This regimen was associated with a 25 percent increase in the VO2 at which the ventilatory threshold (also known as the anaerobic threshold) occurs, and a 52 percent increase in submaximal exercise time (938 to 1429 seconds).",
"   </p>",
"   <p>",
"    Benefits other than a delayed anaerobic threshold and an improvement in submaximal exercise capacity have also been noted after exercise training. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant increase in six-minute walk distance [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. In the 2003 Cochrane review, the mean increase was 41 meters [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/32\">",
"       32",
"      </a>",
"      ]. In the HF-ACTION trial, there was a modest increase in six-minute walk distance at three months but not at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A significant improvement in NYHA functional class (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 16 to 52 percent reduction in resting serum catecholamine concentrations, indicating improved hemodynamics and reduced neurohormonal stimulation [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/39-41\">",
"       39-41",
"      </a>",
"      ]. Decreased sympathetic tone (along with enhanced parasympathetic tone) has also been demonstrated by heart rate variability analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/40\">",
"       40",
"      </a>",
"      ]. This change in the sympathetic-parasympathetic balance is associated with lower resting heart rates [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/37-39,41,42\">",
"       37-39,41,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Exercise training also appears to improve functional capacity in patients with HF with preserved systolic function (HF-PEF) although data are limited as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 16 week randomized controlled trial of 53 patients (mean age 70) with HF-PEF, found that exercise training significantly improved peak VO",
"      <sub>",
"       2",
"      </sub>",
"      , six-minute walk distance, ventilatory threshold, and physical quality of life score (but not the overall quality of life score) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, a 16 week randomized controlled trial of 64 patients (mean age 65) with HF-PEF, found that exercise training significantly improved peak VO",
"      <sub>",
"       2",
"      </sub>",
"      , ventilatory threshold, and physical and overall quality of life scores [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect on patient outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from randomized trials indicates that exercise training may reduce heart failure related hospitalization and improve health-related quality of life in patients with New York Heart Association functional class II or III systolic heart failure (left ventricular ejection fraction &lt;40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/34,45,46\">",
"     34,45,46",
"    </a>",
"    ]. A meta-analysis included 19 randomized controlled trials comparing exercise training and usual care in a total of 3647 patients with New York Heart Association functional class heart failure and left ventricular ejection fraction &lt;40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. There was no significant difference between exercise and control groups in all-cause mortality or overall hospital admissions. Analysis of seven studies with relevant data showed that hospital admission due to heart failure was significantly reduced with exercise training (RR: 0.72, 94% CI: 0.52-0.99). Analysis of 9 studies with relevant data showed that health related quality of life (using various measures) was significantly improved with exercise training (standardized mean difference: -0.57, 95% CI: -0.83 to -0.31).",
"   </p>",
"   <p>",
"    The largest trial included in the meta-analysis was the HF ACTION trial in which 2331 patients with left ventricular ejection fraction &le;35 percent and NYHA class II to IV HF (96 percent with NYHA class II or III symptoms) were randomly assigned to either a supervised exercise training program or usual care including education and recommendation of regular exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/34\">",
"     34",
"    </a>",
"    ]. Background medical therapy was optimized with greater than 90 percent use of angiotensin converting enzyme",
"    <span class=\"nowrap\">",
"     inhibitors/angiotensin",
"    </span>",
"    II receptor blockers and beta blockers. Median follow-up was 30 months. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary composite endpoint was all-cause mortality or all cause hospitalization. There was no significant difference in the primary endpoint upon analysis adjusted for HF etiology (hazard ratio 0.93, 95% CI 0.84-1.02).",
"     </li>",
"     <li>",
"      However, analysis adjusted for major prognostic baseline factors and HF etiology revealed a modest but significant decrease in the primary endpoint with the exercise training program (hazard ratio 0.89, 95% CI 0.81-0.99). After adjustment for prognostic baseline covariates, there was also a significant reduction in cardiovascular mortality or HF hospitalizations (hazard ratio 0.85, 95% CI 0.74-0.99).",
"     </li>",
"     <li>",
"      The trial demonstrated a high level of safety during and after the training sessions. In addition, there was a significant improvement in health status as measured by the Kansas City Cardiomyopathy Questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost-effectiveness of a 14-month exercise training program was assessed in patients with chronic stable HF [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/48\">",
"     48",
"    </a>",
"    ]. Compared to routine management, the estimated increment in life expectancy associated with training was 1.82",
"    <span class=\"nowrap\">",
"     years/person",
"    </span>",
"    over a 15.5 year period, at a cost of $1773 per life-year saved.",
"   </p>",
"   <p>",
"    The economic analysis of HF ACTION showed that more than one-half of costs were related to inpatient care, and that mean unadjusted direct medical costs were lower in the exercise group compared to control. However, taking into account travel costs, patient time, and parking, the cost advantage became nonsignificant [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/49\">",
"     49",
"    </a>",
"    ]. However, the majority of patients with heart failure who are Medicare recipients may not be actively employed. By removing the payment for patient time, the cost advantage becomes significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EXERCISE TRAINING RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon the available data, cardiac rehabilitation should be offered to patients with stable class II to class III HF who do not have advanced arrhythmias, and who do not have other limitations to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/31\">",
"     31",
"    </a>",
"    ]. These recommendations are in general agreement with those published in 2005 by an",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force, which gave exercise training a class I recommendation (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"UTD.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/50\">",
"     50",
"    </a>",
"    ]. The beneficial effects of exercise may be seen with high or low levels of training and are apparent as early as three weeks after training. There are not enough data at present to recommend cardiac rehabilitation for patients with class IV HF.",
"   </p>",
"   <p>",
"    If guided by the HF-ACTION trial, an exercise intensity of 70 percent of heart rate reserve, three days per week for six to eight weeks is a reasonable prescription. Data from HF-ACTION are being reviewed for better on-therapy analysis. The training program was shown to be safe and only modestly beneficial in the endpoints analyzed. The on-therapy analysis may shed more information on the level of exercise needed to produce a beneficial effect.",
"   </p>",
"   <p>",
"    The components of an exercise training program in patients with cardiac disease are discussed in detail separately; in general, they adhere to recommendations published in 2000 by the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/51\">",
"     51",
"    </a>",
"    ] and by the American Heart Association and American Association of Cardiovascular and Pulmonary Rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3000/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=see_link\">",
"       \"Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10496263\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise training in compensated heart failure confers physiologic and clinical benefits. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of exercise in heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical response to exercise training in compensated heart failure is generally not predicted by baseline measures. However, in patients with ischemic cardiomyopathy, the presence of hibernating myocardium favors a positive clinical response to moderate exercise. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Effects of exercise in heart failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise training in compensated heart failure improves left ventricular function and reduces total peripheral resistance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effect on hemodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise training in compensated heart failure (with preserved or reduced left ventricular ejection fraction) improves maximal exercise tolerance. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effect on functional capacity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise training in compensated systolic heart failure may reduce heart failure related hospitalization and improve health related quality of life. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect on patient outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac rehabilitation should be offered to patients with stable NYHA class II to III HF. There are not enough data at present to recommend exercise training for patients with class IV heart failure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Exercise training recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/1\">",
"      Kokkinos PF, Choucair W, Graves P, et al. Chronic heart failure and exercise. Am Heart J 2000; 140:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/2\">",
"      Wilson JR, Martin JL, Ferraro N. Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure: role of cardiac pump dysfunction as determined by the effect of dobutamine. Am J Cardiol 1984; 53:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/3\">",
"      Wilson JR, Martin JL, Ferraro N, Weber KT. Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure. Circulation 1983; 68:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/4\">",
"      Kugler J, Maskin C, Frishman WH, et al. Regional and systemic metabolic effects of angiotensin-converting enzyme inhibition during exercise in patients with severe heart failure. Circulation 1982; 66:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/5\">",
"      Wilson JR, Ferraro N. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure. J Am Coll Cardiol 1985; 6:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/6\">",
"      Walsh JT, Andrews R, Johnson P, et al. Inspiratory muscle endurance in patients with chronic heart failure. Heart 1996; 76:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/7\">",
"      Kitzman DW, Hundley WG, Brubaker PH, et al. A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility. Circ Heart Fail 2010; 3:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/8\">",
"      McKelvie RS, Teo KK, McCartney N, et al. Effects of exercise training in patients with congestive heart failure: a critical review. J Am Coll Cardiol 1995; 25:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/9\">",
"      Belardinelli R, Georgiou D, Cianci G, Purcaro A. Effects of exercise training on left ventricular filling at rest and during exercise in patients with ischemic cardiomyopathy and severe left ventricular systolic dysfunction. Am Heart J 1996; 132:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/10\">",
"      Liu JL, Irvine S, Reid IA, et al. Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: A role for angiotensin II. Circulation 2000; 102:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/11\">",
"      Roveda F, Middlekauff HR, Rondon MU, et al. The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J Am Coll Cardiol 2003; 42:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/12\">",
"      Braith RW, Welsch MA, Feigenbaum MS, et al. Neuroendocrine activation in heart failure is modified by endurance exercise training. J Am Coll Cardiol 1999; 34:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/13\">",
"      Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998; 98:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/14\">",
"      Varin R, Mulder P, Richard V, et al. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation 1999; 99:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/15\">",
"      Hambrecht R, Hilbrich L, Erbs S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000; 35:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/16\">",
"      Wisl&oslash;ff U, St&oslash;ylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 2007; 115:3086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/17\">",
"      Adamopoulos S, Parissis J, Karatzas D, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol 2002; 39:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/18\">",
"      Experience from controlled trials of physical training in chronic heart failure. Protocol and patient factors in effectiveness in the improvement in exercise tolerance. European Heart Failure Training Group. Eur Heart J 1998; 19:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/19\">",
"      Belardinelli R, Georgiou D, Purcaro A. Low dose dobutamine echocardiography predicts improvement in functional capacity after exercise training in patients with ischemic cardiomyopathy: prognostic implication. J Am Coll Cardiol 1998; 31:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/20\">",
"      Belardinelli R, Georgiou D, Ginzton L, et al. Effects of moderate exercise training on thallium uptake and contractile response to low-dose dobutamine of dysfunctional myocardium in patients with ischemic cardiomyopathy. Circulation 1998; 97:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/21\">",
"      Haykowsky MJ, Liang Y, Pechter D, et al. A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. J Am Coll Cardiol 2007; 49:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/22\">",
"      Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: A randomized trial. JAMA 2000; 283:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/23\">",
"      Meyer K, G&ouml;rnandt L, Schwaibold M, et al. Predictors of response to exercise training in severe chronic congestive heart failure. Am J Cardiol 1997; 80:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/24\">",
"      Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999; 99:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/25\">",
"      Whellan DJ, Shaw LK, Bart BA, et al. Cardiac rehabilitation and survival in patients with left ventricular systolic dysfunction. Am Heart J 2001; 142:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/26\">",
"      McKelvie RS, Teo KK, Roberts R, et al. Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). Am Heart J 2002; 144:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/27\">",
"      Otsuka Y, Takaki H, Okano Y, et al. Exercise training without ventricular remodeling in patients with moderate to severe left ventricular dysfunction early after acute myocardial infarction. Int J Cardiol 2003; 87:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/28\">",
"      Radzewitz A, Miche E, Herrmann G, et al. Exercise and muscle strength training and their effect on quality of life in patients with chronic heart failure. Eur J Heart Fail 2002; 4:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/29\">",
"      Tavazzi L, Ignone G. Short-term haemodynamic evolution and late follow-up of post-infarct patients with left ventricular dysfunction undergoing a physical training programme. Eur Heart J 1991; 12:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/30\">",
"      Giannuzzi P, Temporelli PL, Corr&agrave; U, et al. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation 2003; 108:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/31\">",
"      Pi&ntilde;a IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003; 107:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/32\">",
"      Rees K, Taylor RS, Singh S, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2004; :CD003331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/33\">",
"      Smart N, Marwick TH. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity. Am J Med 2004; 116:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/34\">",
"      O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/35\">",
"      Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with chronic heart failure delays ventilatory anaerobic threshold and improves submaximal exercise performance. Circulation 1989; 79:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/36\">",
"      Meyer K, Schwaibold M, Westbrook S, et al. Effects of exercise training and activity restriction on 6-minute walking test performance in patients with chronic heart failure. Am Heart J 1997; 133:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/37\">",
"      Tyni-Lenn&eacute; R, Gordon A, Jansson E, et al. Skeletal muscle endurance training improves peripheral oxidative capacity, exercise tolerance, and health-related quality of life in women with chronic congestive heart failure secondary to either ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Am J Cardiol 1997; 80:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/38\">",
"      Sullivan MJ, Higginbotham MB, Cobb FR. Exercise training in patients with severe left ventricular dysfunction. Hemodynamic and metabolic effects. Circulation 1988; 78:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/39\">",
"      Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J Am Coll Cardiol 1995; 25:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/40\">",
"      Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992; 85:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/41\">",
"      Belardinelli R, Georgiou D, Scocco V, et al. Low intensity exercise training in patients with chronic heart failure. J Am Coll Cardiol 1995; 26:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/42\">",
"      Belardinelli R, Georgiou D, Cianci G, et al. Exercise training improves left ventricular diastolic filling in patients with dilated cardiomyopathy. Clinical and prognostic implications. Circulation 1995; 91:2775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/43\">",
"      Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 2010; 3:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/44\">",
"      Edelmann F, Gelbrich G, D&uuml;ngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011; 58:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/45\">",
"      Davies EJ, Moxham T, Rees K, et al. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev 2010; :CD003331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/46\">",
"      Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail 2010; 12:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/47\">",
"      Flynn KE, Pi&ntilde;a IL, Whellan DJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/48\">",
"      Georgiou D, Chen Y, Appadoo S, et al. Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. Am J Cardiol 2001; 87:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/49\">",
"      Reed SD, Whellan DJ, Li Y, et al. Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes 2010; 3:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/50\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/51\">",
"      Working Group on Cardiac Rehabilitation &amp; Exercice Physiology and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart failure patients. Eur Heart J 2001; 22:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3000/abstract/52\">",
"      Balady GJ, Ades PA, Comoss P, et al. Core components of cardiac rehabilitation/secondary prevention programs: A statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group. Circulation 2000; 102:1069.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3472 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-192C8F5B95-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_3000=[""].join("\n");
var outline_f2_59_3000=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10496263\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EFFECTS OF EXERCISE IN HEART FAILURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effect on hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect on functional capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect on patient outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EXERCISE TRAINING RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10496263\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3472\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3472|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/1/40989\" title=\"table 2\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/16/23813?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/42/21156?source=related_link\">",
"      Patient information: Recovery after coronary artery bypass graft surgery (CABG) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=related_link\">",
"      Skeletal muscle dysfunction and exercise intolerance in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_59_3001="Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults";
var content_f2_59_3001=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3001/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3001/contributors\">",
"     John R Wingard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3001/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3001/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3001/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3001/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/59/3001/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H875810696\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intensive cytotoxic chemotherapy can cause severe and sometimes prolonged neutropenia, which may result in hospitalization for treatment of fever or cause potentially fatal infection. Severe prolonged neutropenia is most likely to occur in the preengraftment phase of hematopoietic cell transplantation (HCT, particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia. One approach to reducing infectious complications involves the use of prophylactic antibacterial, antiviral, and antifungal agents in patients at significant risk of such infections.",
"   </p>",
"   <p>",
"    Because neutropenic patients are unable to mount robust inflammatory responses, serious infection can occur with minimal symptoms and signs. In such patients, fever is often the only sign of infection. Infections in neutropenic patients can progress rapidly, leading to hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other life-threatening complications. Thus, empiric therapy with broad-spectrum antibiotics should be initiated promptly in all febrile neutropenic patients (including those receiving antimicrobial prophylaxis) to reduce the risk of serious morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of prophylactic antibacterial and antiviral agents in high-risk adults will be reviewed here. Infection control precautions for patients with chemotherapy-induced neutropenia will also be discussed. Related topic reviews regarding prophylaxis of infection in neutropenic patients include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"       \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"       \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Topic reviews on neutropenic fever syndromes include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"       \"Overview of neutropenic fever syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"       \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"       \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link\">",
"       \"Fever in children with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1711380205\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1197608611\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of neutropenia varies from institution to institution, but neutropenia is usually defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    and severe neutropenia is usually defined as an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or an ANC that is expected to decrease to &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    over the next 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The risk of clinically-important infection rises as the neutrophil count falls below 500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and is higher in those with a prolonged duration of neutropenia (&gt;7 days). For the purposes of this discussion,",
"    <strong>",
"     we will define neutropenia as an ANC &lt;500",
"     <span class=\"nowrap\">",
"      cells/microL.",
"     </span>",
"    </strong>",
"    <br/>",
"    <br/>",
"    The ANC can be calculated by multiplying the total white blood cell (WBC) count by the percentage of polymorphonuclear cells (PMNs) and bands (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H981551211#H981551211\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Neutropenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of neutropenia\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1711380242\">",
"    <span class=\"h2\">",
"     Risk of serious complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is crucial to assess the risk of serious complications in patients with chemotherapy-induced neutropenia who develop fever (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ). This risk assessment is also relevant for patients in whom antimicrobial prophylaxis is being considered, since prophylaxis is generally indicated for high-risk patients.",
"   </p>",
"   <p>",
"    <strong>",
"     We define high-risk patients as those who are expected to be neutropenic (ANC &lt;500",
"     <span class=\"nowrap\">",
"      cells/microL)",
"     </span>",
"     for &gt;7 days. Patients with neutropenic fever who have ongoing comorbidities or evidence of significant hepatic or renal dysfunction are also considered to be high risk, regardless of the duration of neutropenia.",
"    </strong>",
"    By contrast, low-risk patients are those in whom the duration of neutropenia (ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    is expected to be less than seven days, and who have no comorbidities and no evidence of significant hepatic or renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]. It is important to note that the presence of comorbidities and hepatic or renal dysfunction are important for determining the approach to empiric therapy in patients with neutropenic fever, whereas only the risk of neutropenia (ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    is used for determining the need for prophylaxis.",
"   </p>",
"   <p>",
"    The risk assessment of patients with neutropenic fever is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged neutropenia is most likely to occur in the preengraftment phase of hematopoietic cell transplantation (HCT, particularly allogeneic) and in patients undergoing induction chemotherapy for acute leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811257\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis involves the administration of an antimicrobial drug to prevent neutropenic fever and infectious complications in patients at increased risk. The risk assessment of patients with chemotherapy-induced neutropenia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=see_link\">",
"     \"Risk assessment of adults with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811271\">",
"    <span class=\"h2\">",
"     Antibacterial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibacterial prophylactic regimens target Pseudomonas aeruginosa and other gram-negative bacilli, since these pathogens are particularly virulent and may cause life-threatening infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link&amp;anchor=H9533710#H9533710\">",
"     \"Overview of neutropenic fever syndromes\", section on 'Bacterial pathogens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115683804\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many investigators have sought to determine if the administration of prophylactic antibacterial agents has a beneficial effect on clinical outcomes. The fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg orally once daily) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg orally twice daily) have been studied most extensively, and levofloxacin is favored in patients at increased risk for oral mucositis-related Streptococcus viridans infection [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]. Results have been mixed with respect to effectiveness and have prompted concern about toxicities and antimicrobial resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. At institutions that use fluoroquinolone prophylaxis, systematic monitoring of the prevalence of fluoroquinolone resistance among gram-negative bacilli should be performed.",
"   </p>",
"   <p>",
"    Based upon the available data, we suggest fluoroquinolone prophylaxis for high-risk neutropenic patients (patients anticipated to have an absolute neutrophil count &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for &gt;7 days) who do not have a contraindication to receiving a fluoroquinolone (",
"    <a class=\"graphic graphic_table graphicRef67027 \" href=\"UTD.htm?39/26/40364\">",
"     table 1",
"    </a>",
"    ). High-risk patients include patients undergoing allogeneic hematopoietic cell transplantation (HCT) and patients receiving induction chemotherapy for acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1711380242\">",
"     'Risk of serious complications'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    Antibacterial prophylaxis is sometimes given to intermediate-risk patients, as discussed below. The decision of whether to give antibacterial prophylaxis to intermediate-risk patients should be made on a case-by-case basis. (See",
"    <a class=\"local\" href=\"#H1115683725\">",
"     'Guidelines'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When considering the use of fluoroquinolone prophylaxis, caution is indicated in patients at risk of a prolonged QT interval because QT prolongation is a known toxicity. This is particularly important to consider in patients who may require other QT prolonging agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 2",
"    </a>",
"    ). Tendon rupture has also been reported with fluoroquinolone use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H30#H30\">",
"     \"Fluoroquinolones\", section on 'QT interval prolongation and arrhythmia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link&amp;anchor=H29#H29\">",
"     \"Fluoroquinolones\", section on 'Tendinopathy and tendon rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another important consideration when deciding whether or not to give fluoroquinolone prophylaxis involves the risk of promoting resistance among both gram-negative and gram-positive bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/5\">",
"     5",
"    </a>",
"    ]. There has also been concern about the possibility of increasing the risk of Clostridium difficile infections, although this has not been proven among neutropenic patients receiving fluoroquinolone prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/5\">",
"     5",
"    </a>",
"    ]. In institutions and geographic regions in which there are appreciable rates of fluoroquinolone resistance, the use of these agents for prophylaxis is less likely to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Practices regarding the use of antibacterial prophylaxis vary from center to center, with some centers avoiding the routine use of fluoroquinolone prophylaxis.",
"   </p>",
"   <p>",
"    For most patients with chemotherapy-induced neutropenia expected to be of short duration (which includes standard chemotherapy regimens for most solid tumors), we recommend against the use of antibacterial prophylaxis. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link&amp;anchor=H247552642#H247552642\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\", section on 'Antibacterial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2722434\">",
"    <span class=\"h4\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing for initiating and discontinuing antibacterial prophylaxis has not been adequately studied [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]. When indicated, many clinicians start antibacterial prophylaxis either on the first day of cytotoxic chemotherapy or on the day after the administration of the last dose of the cycle of chemotherapy. It is common to discontinue antibacterial prophylaxis when the neutropenia has resolved, or for patients who become febrile during neutropenia, when an empiric antibacterial regimen is initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115683725\">",
"    <span class=\"h3\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the Infectious Diseases Society of America (IDSA) recommend consideration of fluoroquinolone prophylaxis in patients at high risk for profound prolonged neutropenia (anticipated ANC &le;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    for &gt;7 days). International guidelines for the prevention of infections in HCT recipients recommend fluoroquinolone prophylaxis in patients anticipated to be neutropenic for seven days or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/8\">",
"     8",
"    </a>",
"    ]. As noted above, our approach differs slightly from the IDSA&rsquo;s approach because we consider high-risk patients to be those who are anticipated to have an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (rather than &le;100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    for &gt;7 days. (See",
"    <a class=\"local\" href=\"#H1711380242\">",
"     'Risk of serious complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Combination of a fluoroquinolone plus an antibiotic with enhanced activity against gram-positive organisms is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]. While studies have shown that this approach may reduce infections due to Staphylococcus and Streptococcus spp, and reduce the incidence of neutropenic fever, they do not affect infection-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, increased rates of breakthrough resistant gram-negative and gram-positive bacterial infections have limited the utility of this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/4,5,10,11\">",
"     4,5,10,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1115683592\">",
"     'Evidence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Consensus-based National Comprehensive Cancer Network (NCCN) guidelines suggest consideration of fluoroquinolone prophylaxis for high-risk patients: those undergoing allogeneic HCT, neutropenic patients receiving induction chemotherapy for acute leukemia, and any patient in whom the duration of anticipated neutropenia is &gt;10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/6\">",
"     6",
"    </a>",
"    ]. They also suggest consideration of fluoroquinolone prophylaxis in patients in the following intermediate-risk groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Autologous HCT",
"     </li>",
"     <li>",
"      Lymphoma",
"     </li>",
"     <li>",
"      Chronic lymphocytic leukemia",
"     </li>",
"     <li>",
"      Multiple myeloma",
"     </li>",
"     <li>",
"      Purine analog therapy",
"     </li>",
"     <li>",
"      Anticipated neutropenia 7 to 10 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The decision of whether to give antibacterial prophylaxis to intermediate-risk patients should be made on a case-by-case basis. (See",
"    <a class=\"local\" href=\"#H447665527\">",
"     'Intermediate-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115683592\">",
"    <span class=\"h3\">",
"     Evidence",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447665520\">",
"    <span class=\"h4\">",
"     High-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolones have been evaluated in many clinical trials of prophylaxis for neutropenic patients because of their broad-spectrum of antibacterial activity, favorable safety profiles, and oral bioavailability.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    have been studied most extensively. Ciprofloxacin has greater in vitro activity than levofloxacin against Pseudomonas aeruginosa, but levofloxacin has greater in vitro activity against gram-positive bacteria (eg, alpha-hemolytic streptococci) and is given only once daily compared with twice daily for ciprofloxacin.",
"   </p>",
"   <p>",
"    The following observations have been noted in meta-analyses of prophylaxis trials in neutropenic patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2012 meta-analysis of 109 randomized trials of afebrile neutropenic patients (most of whom had hematologic malignancies or had undergone HCT, with duration of neutropenia &gt;7 days), antibiotic prophylaxis was associated with lower all-cause mortality when compared with placebo or no treatment (relative risk [RR] 0.66, 95% CI 0.55-0.79) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/12\">",
"       12",
"      </a>",
"      ]. Antibiotic prophylaxis was also associated with significantly reduced occurrence of fever, fewer clinically-documented and microbiologically-documented infections, fewer infections due to both gram-positive and gram-negative bacteria, fewer bacteremias, and lower risk of infection-related death.",
"     </li>",
"     <li>",
"      Fluoroquinolone prophylaxis reduced the risk for all-cause mortality (RR 0.54, 95% CI 0.40-0.74), as well as infection-related mortality, fever, clinically-documented infections, and microbiologically-documented infections [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a 2006 meta-analysis, the benefit of antibiotic prophylaxis was found to be greater for high-risk patients than for low-risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/13\">",
"       13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The number of patients needed to treat to prevent one febrile episode was five for leukemia or HCT recipients in contrast to 23 for solid tumor or lymphoma patients.",
"     </li>",
"     <li>",
"      The number of patients needed to treat to prevent one documented infection was six for leukemia or HCT patients versus 13 for solid tumor or lymphoma patients.",
"     </li>",
"     <li>",
"      The number needed to treat to prevent one death was 43 for leukemia or HCT patients versus 132 for solid tumor or lymphoma patients [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluoroquinolone prophylaxis was associated with trends to higher rates for colonization with resistant bacteria in a 2007 meta-analysis that focused on this issue [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/14\">",
"       14",
"      </a>",
"      ]. This concern requires ongoing vigilance and surveillance and may vary from center to center.",
"     </li>",
"     <li>",
"      Prophylactic antibiotics were associated with an increased risk for adverse events, primarily gastrointestinal toxicities [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) was evaluated in older trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/12\">",
"     12",
"    </a>",
"    ], but it is no longer used since it has no activity against P. aeruginosa. In addition, susceptibility to TMP-SMX among a variety of bacterial species has declined worldwide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38438?source=see_link&amp;anchor=H3#H3\">",
"     \"Trimethoprim-sulfamethoxazole: An overview\", section on 'Resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447665527\">",
"    <span class=\"h4\">",
"     Intermediate-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluoroquinolone prophylaxis is sometimes used in selected intermediate-risk patients whose treatment regimens generally result in 7 to 10 days of neutropenia (eg, autologous HCT recipients; patients with lymphoma, chronic lymphocytic leukemia, or multiple myeloma; patients receiving a purine analog) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/6\">",
"     6",
"    </a>",
"    ]. The decision of whether to give antibacterial prophylaxis to intermediate-risk patients should be made on a case-by-case basis. Although several studies have shown benefits in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], the magnitude of benefit is less than with high-risk patients, and a survival benefit has not been definitively demonstrated. One should weigh the benefits versus the risk that wider use in more patients may increase the risk for the emergence of resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H447665534\">",
"    <span class=\"h4\">",
"     Low-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence regarding antibacterial prophylaxis in low-risk patients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link&amp;anchor=H247552642#H247552642\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\", section on 'Antibacterial prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811278\">",
"    <span class=\"h2\">",
"     Antifungal prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relatively high incidence of life-threatening invasive fungal infections (eg, candidemia) among cancer patients and HCT recipients since the late 1980s has prompted interest in antifungal prophylaxis for patients receiving chemotherapy. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811285\">",
"    <span class=\"h3\">",
"     PCP prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumocystis pneumonia (PCP) prophylaxis is used in certain patients, such as allogeneic HCT recipients, selected autologous HCT recipients, and in some patients receiving induction chemotherapy for acute lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Hematopoietic stem cell transplant recipients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811292\">",
"    <span class=\"h2\">",
"     Antiviral prophylaxis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636049673\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of influenza virus should be considered well in advance of the development of neutropenia. Annual immunization with an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    is recommended for all patients being treated for cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the optimal timing for such immunization has not been established, the influenza vaccine is generally administered &gt;2 weeks before chemotherapy starts or, when circumstances dictate, between chemotherapy cycles and at least seven days after the last cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]. Annual immunization of all family members and other close contacts is also recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemoprophylaxis to prevent influenza virus is indicated under certain circumstances. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of seasonal influenza in adults\", section on 'Indications for chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636049666\">",
"    <span class=\"h3\">",
"     HSV and VZV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of herpes simplex virus-1 (HSV-1) and HSV-2 are important causes of morbidity in patients with acute leukemia and those undergoing HCT. In addition, varicella-zoster virus (VZV) reactivation occurs commonly in HCT recipients who are not receiving prophylaxis. Both HSV and VZV infections can be effectively prevented with antiviral prophylaxis. Patients who are seropositive for HSV and who are undergoing allogeneic HCT or induction chemotherapy for acute leukemia should receive antiviral prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (400 mg orally three to four times daily or 800 mg orally twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg orally once or twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/8\">",
"     8",
"    </a>",
"    ]. HCT recipients who are seropositive for VZV should also receive antiviral prophylaxis with one of these agents. These recommendations are based upon randomized trials demonstrating benefit in these populations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HSV prophylaxis is usually continued until recovery of the white blood cell count or resolution of mucositis, whichever occurs later; it can be extended for a longer period in patients with frequent recurrent HSV infections or in those with graft-versus-host disease (GVHD) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. In HCT recipients who are seropositive for VZV, antiviral prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (800 mg orally twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    (500 mg orally twice daily) is typically continued for one year, or longer in those with chronic GVHD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who require ongoing immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636049659\">",
"    <span class=\"h3\">",
"     CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactivation of cytomegalovirus (CMV) does not occur commonly in patients with chemotherapy-induced neutropenia, and CMV prophylaxis or preemptive therapy is therefore not indicated. In contrast, HCT recipients are at significant risk for CMV reactivation. Strategies for the prevention of CMV disease in HCT recipients are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1636049540\">",
"    <span class=\"h3\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving chemotherapy who have a history of previous hepatitis B virus infection are at risk of reactivation with a flare of hepatitis that may potentially result in hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients with elevated circulating hepatitis B DNA or detectable levels of circulating hepatitis B surface antigen (HBsAg) are at particular risk. Those who have been infected and who have cleared the virus from the circulation and who have developed antibody to HBsAg or to hepatitis B core antigen are also at risk. Antiviral prophylaxis should be considered for such patients at risk for reactivation and should be continued for at least six months after the completion of chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/20\">",
"     20",
"    </a>",
"    ]. This strategy can reduce the risk of reactivation from 24 to 53 percent to 0 to 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/21\">",
"     21",
"    </a>",
"    ]. The choice of agent is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811299\">",
"    <span class=\"h2\">",
"     Colony stimulating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IDSA guidelines recommend that the prophylactic use of colony stimulating factors (CSFs; also known as myeloid growth factors or hematopoietic growth factors), such as granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF), be considered for afebrile patients in whom the anticipated risk of fever and neutropenia is &ge;20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811306\">",
"    <span class=\"h2\">",
"     Vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines for the prevention of infection in cancer patients and hematopoietic cell transplant recipients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"     \"Immunizations in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"     \"Immunizations after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811313\">",
"    <span class=\"h2\">",
"     Infection control precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several precautions should be taken while caring for neutropenic patients with cancer to prevent transmission of infection in the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hand hygiene should be used; this is the most effective measure for preventing the transmission of infection.",
"     </li>",
"     <li>",
"      No specific protective gear (eg, gowns, gloves, masks) is required during the routine care of neutropenic patients, but standard barrier precautions should be used for all patients (ie, when contact with body fluids is anticipated), and infection-specific isolation precautions should be used for patients with signs and symptoms of certain infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"       \"General principles of infection control\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=see_link\">",
"       \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HCT recipients should be placed in private rooms with &gt;12 air exchanges per hour and high-efficiency particulate air (HEPA) filtration.",
"     </li>",
"     <li>",
"      Plants and dried or fresh flowers should",
"      <strong>",
"       not",
"      </strong>",
"      be allowed in the hospital rooms of neutropenic patients.",
"     </li>",
"     <li>",
"      Hospital work exclusion policies should be created to encourage health care workers and other hospital staff to report their illnesses or exposures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115681900\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF NEUTROPENIC FEVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy with broad-spectrum antibiotics should be initiated promptly in all febrile neutropenic patients to reduce the risk of serious morbidity and mortality, including patients who have been receiving antimicrobial prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3001/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H875811813\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2723936\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensive cytotoxic chemotherapy can cause severe and sometimes prolonged neutropenia, which may result in hospitalization for treatment of fever or cause potentially fatal infection. One approach to reducing infectious complications involves the use of prophylactic antibacterial, antiviral, and antifungal agents in patients at significant risk of such infections. (See",
"      <a class=\"local\" href=\"#H875810696\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is crucial to assess the risk of serious complications in patients with chemotherapy-induced neutropenia; prophylaxis is generally indicated for high-risk patients, defined as those who are anticipated to have an absolute neutrophil count (ANC) &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for &gt;7 days. (See",
"      <a class=\"local\" href=\"#H1711380242\">",
"       'Risk of serious complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2723944\">",
"    <span class=\"h2\">",
"     Antibacterial prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest fluoroquinolone prophylaxis for high-risk neutropenic patients (patients anticipated to have an ANC &lt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      for &gt;7 days) who do not have a contraindication to receiving a fluoroquinolone (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). High-risk patients include those undergoing allogeneic HCT and those receiving induction chemotherapy for acute leukemia.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       Levofloxacin",
"      </a>",
"      (500 mg orally once daily) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (500 mg orally twice daily) have been studied most extensively, and levofloxacin is favored in patients with increased risk for oral mucositis-related Streptococcus viridans infection. (See",
"      <a class=\"local\" href=\"#H1115683804\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1115683725\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluoroquinolone prophylaxis is sometimes used in selected intermediate-risk patients whose treatment regimens generally result in 7 to 10 days of neutropenia (eg, autologous HCT recipients; patients with lymphoma, chronic lymphocytic leukemia, or multiple myeloma; patients receiving a purine analog). The decision of whether to give antibacterial prophylaxis to intermediate-risk patients should be made on a case-by-case basis. (See",
"      <a class=\"local\" href=\"#H1115683725\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several potential downsides to using fluoroquinolone prophylaxis, including toxicities and the potential for promoting resistance. Practices regarding the use of antibacterial prophylaxis vary from center to center, with some centers avoiding the routine use of fluoroquinolone prophylaxis. At institutions that use fluoroquinolone prophylaxis, systematic monitoring of the prevalence of fluoroquinolone resistance among gram-negative bacilli should be performed. (See",
"      <a class=\"local\" href=\"#H1115683804\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are at risk for neutropenia, we recommend against the addition of a prophylactic antibacterial agent with specific activity against gram-positive organisms (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1115683725\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with chemotherapy-induced neutropenia expected to be of short duration (which includes standard chemotherapy regimens for most solid tumors), we recommend against the use of antibacterial prophylaxis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1115683804\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2724024\">",
"    <span class=\"h2\">",
"     Antifungal and antiviral prophylaxis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antifungal prophylaxis is used in certain high-risk patients with chemotherapy-induced neutropenia. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=see_link\">",
"       \"Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend antiviral prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"       valacyclovir",
"      </a>",
"      for all patients who are seropositive for herpes simplex virus who are undergoing allogeneic HCT or induction chemotherapy for acute leukemia (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We also recommend antiviral prophylaxis for HCT recipients who are seropositive for varicella-zoster virus (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Strategies for the prevention of cytomegalovirus in HCT recipients are discussed separately. (See",
"      <a class=\"local\" href=\"#H875811292\">",
"       'Antiviral prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"       \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2724145\">",
"    <span class=\"h2\">",
"     Other measures",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vaccines for the prevention of infection in cancer patients and HCT recipients are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=see_link\">",
"       \"Immunizations in patients with cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=see_link\">",
"       \"Immunizations after hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prophylactic use of colony stimulating factors (CSFs), such as granulocyte and granulocyte-macrophage colony stimulating factors (G-CSF and GM-CSF) should be considered for afebrile patients in whom the anticipated risk of fever and neutropenia is &ge;20 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"       \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Empiric therapy with broad-spectrum antibiotics should be initiated promptly in",
"      <strong>",
"       all",
"      </strong>",
"      febrile neutropenic patients, including patients who have been receiving antimicrobial prophylaxis, to reduce the risk of serious morbidity and mortality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H204544771\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Richard A Larson, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/1\">",
"      Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE). file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on February 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/3\">",
"      Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/4\">",
"      Wingard JR, Eldjerou L, Leather H. Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. Curr Opin Hematol 2012; 19:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/5\">",
"      Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011; 24:545.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Prevention and treatment of cancer-related infections. Version 1.2012. file://www.nccn.org (Accessed on January 03, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/7\">",
"      Ng ES, Liew Y, Koh LP, Hsu LY. Fluoroquinolone prophylaxis against febrile neutropenia in areas with high fluoroquinolone resistance--an Asian perspective. J Formos Med Assoc 2010; 109:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/8\">",
"      Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/9\">",
"      Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. JAMA 1994; 272:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/10\">",
"      Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/11\">",
"      Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 2010; 116:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/12\">",
"      Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 1:CD004386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/13\">",
"      Leibovici L, Paul M, Cullen M, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006; 107:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/14\">",
"      Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007; 59:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/15\">",
"      Eleutherakis-Papaiakovou E, Kostis E, Migkou M, et al. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol 2010; 85:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/16\">",
"      Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/17\">",
"      Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/18\">",
"      Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983; 99:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/19\">",
"      Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study. Blood 2006; 107:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/20\">",
"      Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3001/abstract/21\">",
"      Firpi RJ, Nelson DR. Viral hepatitis: manifestations and management strategy. Hematology Am Soc Hematol Educ Program 2006; :375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1153 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-72FD83CAD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_3001=[""].join("\n");
var outline_f2_59_3001=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H875811813\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H875810696\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1711380205\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1197608611\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1711380242\">",
"      Risk of serious complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H875811257\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H875811271\">",
"      Antibacterial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1115683804\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2722434\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1115683725\">",
"      - Guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1115683592\">",
"      - Evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447665520\">",
"      High-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447665527\">",
"      Intermediate-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H447665534\">",
"      Low-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H875811278\">",
"      Antifungal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H875811285\">",
"      - PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H875811292\">",
"      Antiviral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1636049673\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1636049666\">",
"      - HSV and VZV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1636049659\">",
"      - CMV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1636049540\">",
"      - Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H875811299\">",
"      Colony stimulating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H875811306\">",
"      Vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H875811313\">",
"      Infection control precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1115681900\">",
"      MANAGEMENT OF NEUTROPENIC FEVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H875811813\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2723936\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2723944\">",
"      Antibacterial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2724024\">",
"      Antifungal and antiviral prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2724145\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H204544771\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1153|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/26/40364\" title=\"table 1\">",
"      High-risk patients with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 2\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25498?source=related_link\">",
"      Immunizations after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/37/30296?source=related_link\">",
"      Immunizations in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29178?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adult hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/25/39320?source=related_link\">",
"      Risk assessment of adults with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38438?source=related_link\">",
"      Trimethoprim-sulfamethoxazole: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_59_3002="Intensity of lipid lowering therapy in secondary prevention of coronary heart disease";
var content_f2_59_3002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3002/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3002/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3002/contributors\">",
"     Rodney A Hayward, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3002/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3002/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/59/3002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/59/3002/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/59/3002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known coronary heart disease (CHD) or coronary equivalents (as defined below) are at high risk for cardiovascular events. Statins have been shown to reduce such events, and to reduce all-cause mortality. Trials of other lipid-lowering agents have generally only shown reductions in cardiovascular events.",
"   </p>",
"   <p>",
"    Trials of statins have provided additional information that is related to the appropriate serum low density lipoprotein cholesterol (LDL-C) target in patients being treated for secondary prevention. However, the results of these trials are open to various interpretations and the ideal target LDL-C level has not been completely defined.",
"   </p>",
"   <p>",
"    This topic will review the evidence for LDL-C goals in patients treated with statins for secondary prevention of CHD, as well as the evidence for using agents other than statins in patients who are unable to tolerate statins or do not achieve LDL-C goals with statins alone. The general approach to lipid lowering therapy for secondary prevention and in patients with an acute coronary syndrome, as well as an overview of the treatment of hypercholesterolemia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link&amp;anchor=H9#H9\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Lipid modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to known coronary heart disease (CHD), the following conditions are considered to be coronary equivalents that require management as if treatment were for secondary prevention of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Many patients with diabetes mellitus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H1033672373#H1033672373\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Diabetes mellitus as a CHD equivalent'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Symptomatic carotid artery disease",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Abdominal aortic aneurysm",
"     </li>",
"     <li>",
"      Multiple risk factors that confer a 10-year risk of CHD &gt;20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the above conditions identified by the Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP III) as CHD equivalents, we consider chronic kidney disease (defined by a plasma creatinine concentration that exceeds 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    or an estimated glomerular filtration rate that is less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) to be a CHD equivalent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Chronic kidney disease as an independent risk factor for CHD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTENSIVE THERAPY WITH STATINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2002 ATP III report recommended that for secondary prevention, dietary modification be employed in any patient with an LDL-C exceeding 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and drug therapy be given if the LDL-C remains above 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82504 \" href=\"UTD.htm?11/4/11340\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/1\">",
"     1",
"    </a>",
"    ]. Drug therapy was considered optional in patients with LDL-C values between 100 and 129",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6 to 3.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional studies published after the ATP III report led the Coordinating Committee of the National Cholesterol Education Program (NCEP) to propose modifications to the ATP III guidelines that recommended initiating drug therapy for patients with an LDL-C above 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and CHD or CHD equivalents, and consideration of an optional goal LDL below 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    particularly in very high-risk patients (",
"    <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67460 \" href=\"UTD.htm?10/46/10989\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the trials used to support more aggressive lipid-lowering recommendations have not shown consistent benefits across outcomes, either finding no reductions in all-cause mortality and cardiovascular mortality or only finding reductions in cardiovascular mortality. Even these latter findings are somewhat surprising, since cardiovascular mortality is a major component of total mortality in the populations studied.",
"   </p>",
"   <p>",
"    A 2011 meta-analysis of randomized trials comparing intensive with moderate statin therapy that included patients with both stable CHD and acute coronary syndrome (ACS) found that intensive therapy did not result in a statistically significant reduction in all-cause mortality (relative risk [RR] 0.92, 95% CI 0.83-1.03) or cardiovascular mortality (RR 0.89, CI 0.78-1.01), however there was moderate heterogeneity of results across the included trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/3\">",
"     3",
"    </a>",
"    ]. In the subgroup of trials of patients with ACS, intensive therapy reduced mortality (RR 0.75, CI 0.61-0.91) and cardiovascular mortality (RR 0.74, CI 0.59-0.94) and there was no heterogeneity. In the subgroup of trials of patients with stable CHD, intensive therapy did not reduce all-cause mortality (0.95, CI 0.85-1.06) or cardiovascular mortality (0.97, CI 0.87-1.03), although there was some remaining heterogeneity across trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the largest of these trials are discussed in more depth below as the details of these trials are important in understanding why there is disagreement about whether targeting lower LDL-C goals or using more intensive statin regimens is beneficial.",
"   </p>",
"   <p>",
"    Among the available choices for intensive statin therapy, the two most potent regimens are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg daily and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    40 mg daily. In the SATURN trial, in 1039 patients with known coronary disease, these two regimens had similar effects on the surrogate primary outcome of percent atheroma volume and also had similar clinical outcomes and rates of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H648157811#H648157811\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'SATURN trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trials providing background",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Heart Protection Study suggested that statins are beneficial even in patients with low LDL-C levels, while the REVERSAL trial found evidence of improvement in the surrogate endpoint of coronary plaque volume with more intensive statin therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Heart Protection Study (HPS) compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      40 mg daily with placebo in patients with diabetes or known CHD and showed a consistent and early benefit of statin therapy, including in those patients with LDL-C values below 116",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.0",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      and even below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/6\">",
"       6",
"      </a>",
"      ]. While this supports the idea that nearly all patients with CHD may benefit from statins regardless of LDL-C prior to statin therapy, it does not prove that a lower target LDL-C is better. Another possibility is that a statin is beneficial independent of the pretreatment or posttreatment LDL-C.",
"      <br/>",
"      <br/>",
"      Of note, the LDL-C levels in HPS were measured values rather than the calculated values used in most earlier trials, observational studies, and clinical practice. Measured LDL-C is typically lower than calculated LDL-C, making the starting and target LDL-C levels in HPS appear somewhat lower than the values clinicians are typically familiar with. Goal LDL-C recommendations are usually based upon calculated LDL-C levels. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pleiotropic effects'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H28#H28\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Heart Protection Study'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The REVERSAL trial assessed changes in coronary plaque volume over 18 months using intravascular ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients who were treated with intensive lipid-lowering therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily had a reduction in LDL-C to 79",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and had no change in median plaque volume (plaque did not progress), while patients treated with standard therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      40 mg daily had a reduction in LDL-C to 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and had a 2.7 percent increase in median plaque volume. The study was not designed to look for differences in cardiac events or mortality and had inadequate power to detect such differences. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'REVERSAL trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H887355543\">",
"    <span class=\"h2\">",
"     Trials showing mortality benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have found mortality benefits with more intensive statin therapy. The two large trials showing such benefits were in patients with acute coronary syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SAGE trial compared intensive and standard statin therapy in 893 patients with known CHD ages 65 to 85 who had at least one episode of ischemia on baseline screening with 48-hour ambulatory monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/8\">",
"       8",
"      </a>",
"      ]. Patients were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      40 mg daily. There was no difference between the two groups in the primary endpoint of duration of ischemia on ambulatory monitoring at month 12. However, there was a trend toward a reduction in a composite endpoint of major cardiovascular events with intensive therapy (hazard ratio [HR] 0.71, 95% CI 0.46-1.09), and there was a significant reduction in mortality (HR 0.33, CI 0.13-0.83). Mortality was considered as an endpoint post hoc, and the magnitude of the reduction in mortality seems larger than would be expected in such a trial, particularly given the lack of mortality benefit seen in the much larger TNT and IDEAL trials discussed below; no mortality benefit with intensive therapy was seen in patients ages 65 and over (n = 3809) studied in the TNT trial [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The PROVE IT-TIMI 22 trial showed that patients with an acute coronary syndrome who were treated with intensive lipid-lowering therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily had a reduction in clinical events as compared to patients treated with standard therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      40 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/10\">",
"       10",
"      </a>",
"      ]. The benefit began within 30 days, and the absolute benefit increased over time, such that the rate of patients reaching a composite primary end point was significantly lower with atorvastatin after two years (22.4 versus 26.3 percent) (",
"      <a class=\"graphic graphic_table graphicRef78178 \" href=\"UTD.htm?14/49/15131\">",
"       table 4",
"      </a>",
"      ). Patients treated with atorvastatin had a decrease in mortality that was not statistically significant (relative risk 0.72, p = 0.07); however, a reduction in risk of this magnitude is similar to that seen in studies that compared statins with placebo and would be clinically important if real. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link&amp;anchor=H4#H4\">",
"       \"Cholesterol lowering after an acute coronary syndrome\", section on 'PROVE IT-TIMI 22 trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phase Z of the A to Z trial compared an aggressive statin strategy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      40 mg daily for one month followed by 80 mg daily thereafter) with a delayed conservative strategy (placebo for four months followed by simvastatin 20 mg thereafter) in 4497 patients with an acute coronary syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/11\">",
"       11",
"      </a>",
"      ]. Unlike PROVE IT-TIMI 22, no early benefit was seen with the aggressive statin strategy. However, after a median follow-up of approximately two years, there was a decrease in mortality that was not statistically significant (HR 0.79, 95% CI 0.61-1.02), but would be clinically significant if real.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trials not showing mortality benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the acute coronary syndrome trials that showed strong trends toward mortality benefit, three large trials comparing high dose statin therapy with standard therapy in patients with stable CHD found no benefit on all-cause mortality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TNT trial randomly assigned 10,001 patients with stable coronary heart disease to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      at a low dose (10 mg daily) with a goal LDL-C of 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or a high dose (80 mg daily) with a goal LDL-C of 75",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/12\">",
"       12",
"      </a>",
"      ]. The following findings were noted with high dose atorvastatin (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H20#H20\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'TNT trial'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A lower mean serum LDL-cholesterol concentration (77 versus 101",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.0 versus 2.6",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      A significant 22 percent reduction in a combined cardiovascular endpoint, and a 20 percent reduction in cardiac deaths.",
"     </li>",
"     <li>",
"      Despite the cardiovascular benefit, no reduction was seen in overall mortality (hazard ratio [HR] 1.01, 95% CI 0.85-1.19). This was due to a 25 percent increase in noncardiovascular deaths in patients receiving high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      . These noncardiovascular deaths were not due to any one single factor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IDEAL was an open label trial that randomly assigned 8888 patients with a past history of acute MI to receive intensive lipid lowering therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily or standard lipid lowering therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      20 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/13\">",
"       13",
"      </a>",
"      ]. After a median follow-up of 4.8 years, the following findings were seen with atorvastatin compared with simvastatin (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H21#H21\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'IDEAL trial'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A lower LDL-C concentration (81 versus 104 mg",
"      <span class=\"nowrap\">",
"       /dL",
"      </span>",
"      [2.1 versus 2.7",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      A statistically nonsignificant 11 percent reduction in the primary endpoint of time to first occurrence of a major coronary event defined as coronary death, hospitalization for acute MI, or cardiac arrest (9.3 versus 10.4 percent, hazard ratio [HR] 0.89, 95% CI 0.78-1.01).",
"     </li>",
"     <li>",
"      A reduction in a number of secondary endpoints including nonfatal myocardial infarction (6 versus 7.2 percent, HR 0.83, CI 0.71-0.98) and coronary revascularization (13.0 versus 16.6 percent, HR 0.77, CI 0.69-0.86).",
"     </li>",
"     <li>",
"      No effect on all-cause mortality (HR 0.98, CI 0.85-1.13), cardiovascular mortality (HR 1.03, CI 0.85-1.24) or noncardiovascular mortality (HR 0.92, CI 0.73-1.15).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) randomly assigned 12,064 patients with a prior history of MI to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      80 mg daily or simvastatin 20 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/14\">",
"       14",
"      </a>",
"      ]. The primary composite endpoint was major vascular events (coronary death, MI, stroke, or arterial revascularization). The following findings were seen with high dose compared with low dose simvastatin after a median follow-up of 6.7 years (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H719305722#H719305722\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'SEARCH trial'",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.35",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      lower LDL-C concentration",
"     </li>",
"     <li>",
"      A statistically nonsignificant reduction in the primary endpoint (24.5 versus 25.7 percent, risk ratio [RR] 0.94, 95% CI 0.88-1.01)",
"     </li>",
"     <li>",
"      No effect on all cause mortality (RR 0.99, CI 0.91-1.09), vascular mortality (RR 0.99, CI 0.88-1.11), or nonvascular mortality (RR 1.00, CI 0.87-1.15)",
"     </li>",
"     <li>",
"      A higher rate of creatine kinase elevations including those more than 40 times the upper limit of normal (0.4 versus 0.0 percent), incipient myopathy (1.4 versus 0.2 percent), definite myopathy without rhabdomyolysis (0.9 versus 0.0 percent), and rhabdomyolysis (0.1 versus 0.0 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Earlier studies of lipid-lowering therapy with medications other than statins showed trends toward reductions in cardiovascular events with increases in noncardiac mortality similar to those seen in TNT. The results of IDEAL and SEARCH, however, are reassuring that more intensive statin therapy does not appear to increase noncardiovascular mortality even if it has little or no effect on all-cause mortality in patients with stable CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pleiotropic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence on statins, whether at standard or intensive doses, does not allow a simple way to sort out whether the benefits are due to the degree of lowering of LDL-C or to some other effect of statins.",
"   </p>",
"   <p>",
"    Some part of the benefits of statin therapy is believed to be due to \"pleiotropic\" effects separate from the effect on LDL-C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If this is the case, then some portion of benefits from statins may be determined by the specific type of statin used or by the dose of statin, independent of the effects on LDL-C. Future studies that achieve the same LDL-C goals with multiple medications may help solve this puzzle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Statin dose versus goal LDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The idea of targeting statin dosing to achieve a specific goal LDL-C is central to most major lipid guidelines (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=see_link\">",
"     \"ATP III guidelines for treatment of high blood cholesterol\"",
"    </a>",
"    ). However, LDL reduction was a post-randomization intermediate outcome in these studies and, therefore, its correlation with other study endpoints represents an observational finding. None of the analyses to date adequately control for all major confounders, especially adherence to statin therapy, and non-randomized trials cannot control for unknown and unmeasured confounders. In the absence of clinical trials that specifically target a goal LDL-C, the evidence for goal LDL-C is based on relatively low quality observational data of achieved LDL, even though these observations were made in the context of randomized trials. This remains the case even when large-scale meta-analyses are performed that model the association between reductions in LDL-C and reductions in cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Heart Protection Study (HPS), there was a four to six week prerandomization run-in period where all patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40 mg daily and the LDL response was measured [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/6\">",
"     6",
"    </a>",
"    ]. This allowed a valid subgroup analysis based upon prerandomization achieved LDL. The reduction in the primary outcome (first major cardiovascular event) was similar for patients with a smaller (&lt;38 percent), average, or larger (&gt;48 percent) change in LDL-C during the run-in period, which does not support the contention that the benefit with simvastatin is related to the achieved LDL-C.",
"   </p>",
"   <p>",
"    In addition, LDL measurement in clinical practice has a number of problems including measurement error, short-term and long-term variability in LDL, and the potentially greater importance of LDL subparticles than total LDL.",
"   </p>",
"   <p>",
"    No study has directly assessed the benefits of a strategy of increasing the statin dose to achieve a specific recommended LDL-C level or the safety or efficacy of multidrug therapy in pursuit of proposed LDL-C goals.",
"   </p>",
"   <p>",
"    An alternative strategy would be to dose statins based on the doses found to be beneficial in clinical trials, without regard to the achieved LDL-C reduction. Measurement of LDL-C in patients on therapy would then be performed only to confirm medication adherence or perhaps to guide intensification of therapy for the small percentage of patients whose LDL-C levels remain very far from optimal targets. Dosing statins in this way also has implications for patients with low baseline LDL-C levels such as those seen in some patients with type 1 diabetes. Low doses of statins (eg, less than 40 mg daily of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ) have not been well evaluated. Rather than not treating patients who are already at or near goal LDL-C, or treating them with a low statin dose, this strategy would suggest that CHD patients and those with CHD equivalents be treated with at least moderate statin doses even if LDL-C goals are achievable with lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least in the setting of acute myocardial infarction, the evidence of early benefit with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    80 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/10\">",
"     10",
"    </a>",
"    ], but not with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    40 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/11\">",
"     11",
"    </a>",
"    ], supports the notion of administering statins based on the doses used in clinical trials rather than targeting LDL-C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One piece of the counter argument for targeting LDL-C rather than statin dose has come from an analysis of event rates across trials based on the achieved LDL-C (",
"    <a class=\"graphic graphic_figure graphicRef55856 \" href=\"UTD.htm?1/18/1326\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the studies used in this comparison differ from each other in many ways (eg, time period, country, baseline risk, crossover, medication adherence) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/17\">",
"     17",
"    </a>",
"    ]. When the same data are replotted separating the statin and placebo arms, statins appear to have an effect independent of LDL-C, and when the data are further replotted using each study as its own control, the relationship between event rate and achieved LDL-C is far less convincing (",
"    <a class=\"graphic graphic_figure graphicRef52999 \" href=\"UTD.htm?33/36/34383\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dose-based strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dose-based strategy might include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treat high-risk patients (those with stable CHD or at high CHD risk such as CHD risk equivalents) with a moderate dose of a statin (eg, 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , or 5 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      ) rather than targeting a goal LDL-C.",
"     </li>",
"     <li>",
"      Treat patients at very high risk for CHD events such as those in the proposed NCEP guidelines (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 2",
"      </a>",
"      ) with an intensive statin regimen (eg, 40 to 80 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , 20 to 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      ) rather than targeting a goal LDL-C. All patients treated with intensive statin therapy should be carefully monitored for side effects with reduction of the statin dose if indicated.",
"     </li>",
"     <li>",
"      Measure LDL-C on treatment for the following purposes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Adherence should be confirmed in patients who do not have an appropriate drop in LDL-C on statin therapy or who have an increase in LDL-C after an initial response to therapy.",
"     </li>",
"     <li>",
"      Decrease the intensity of statin therapy in patients whose LDL-C on therapy is below 25",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.65",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Minimum LDL'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients not already on intensive statin therapy, increase the intensity of statin therapy in high-risk patients with an LDL-C above 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.36",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and in very-high-risk patients (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 2",
"      </a>",
"      ) with an LDL-C above 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.59",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Patients should be carefully monitored for side effects with reduction of the statin dose if indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of an indication other than prevention of CHD, do not treat patients with another lipid-lowering medication in combination with a statin even if the LDL-C does not achieve the above goals.",
"     </li>",
"     <li>",
"      In high-risk and very-high-risk patients who do not tolerate statin therapy as above, treat with low dose statin therapy if tolerated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"       \"Statins: Actions, side effects, and administration\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treat very-high-risk patients (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 2",
"      </a>",
"      ) who do not tolerate statin therapy with another lipid-lowering medication. In the absence of an indication other than prevention of CHD, only treat high-risk patients who do not tolerate a statin with another lipid-lowering medication if the LDL-C is far from optimal (eg, above 160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.14",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A simulation using computer modeling suggested that, compared with treating to LDL targets, a strategy similar to the dose-based regimens presented above (ie, moderate dose-potency statin regimens for moderate risk patients, and high dose-potency statin regimens for high risk patients) would prevent more CHD events while treating fewer patients with high-dose statins, in patients without a history of MI [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Minimum LDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;With a dose-based strategy, or even a goal LDL strategy, clinicians may occasionally encounter patients who achieve very low LDL-C levels on treatment. There is little or no high quality evidence by which to determine the minimum safe value of LDL-C. In the JUPITER trial, patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    who attained an LDL-C below 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    had a slightly higher rate of adverse events than those who did not (108.1 versus 104.0 adverse events per 100 person-years); this may reflect greater adherence with therapy in patients who attained lower LDL-C levels [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/19\">",
"     19",
"    </a>",
"    ]. This higher rate of overall adverse events was not driven by any particular class of adverse event and, in particular, musculoskeletal and neurologic event rates were similar in the two groups.",
"   </p>",
"   <p>",
"    Patients with some genetic mutations can have LDL-C concentrations below 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    without apparent harm. Some patients with genetic disorders that result in very low concentrations of LDL-C (eg, below 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.65",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    develop neurologic and metabolic abnormalities that could be related, at least in part, to the very low levels of LDL-C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Abetalipoproteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until higher quality evidence regarding the safety of very LDL-C levels is available, we suggest a reduction in statin dose in patients who achieve an LDL-C on treatment below 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.65",
"    <span class=\"nowrap\">",
"     mmol/L].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Putting the evidence together",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence appears to show a clear mortality benefit for most patients treated with statins for secondary prevention of CHD. In addition, high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    appears to be superior to standard dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    in patients being treated for an acute coronary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H35#H35\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Early use of statins after an ACS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"     \"Cholesterol lowering after an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this, three large trials (combined population of more than 30,000 patients) of intensive statin therapy for secondary prevention in patients with",
"    <strong>",
"     stable",
"    </strong>",
"    &nbsp;",
"    <strong>",
"     CHD",
"    </strong>",
"    found decreases or trends toward decreases in cardiovascular events but no decrease in all-cause mortality compared with lower intensity statin therapy; two of the three trials also found no additional reduction in cardiovascular mortality.",
"   </p>",
"   <p>",
"    In addition, higher doses of statins are generally less well tolerated than lower doses, with higher rates of side effects including muscle and liver toxicity (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/14,20-22\">",
"     14,20-22",
"    </a>",
"    ]. For many patients, these side effects are minor (muscle pain or asymptomatic elevations of aminotransferases), however these may lead to patients discontinuing statin therapy and thus losing the clear mortality benefits of taking a statin rather than no therapy. In IDEAL, more than twice as many people discontinued high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    compared with usual dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (9.6 versus 4.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even if high dose statins do not decrease all-cause mortality in patients with stable CHD, it may be reasonable to use such doses to reduce cardiovascular events other than death. Although IDEAL did not show a statistically significant decrease in its primary cardiovascular endpoint, the results approached significance, and a similar endpoint was lower in TNT. Implementing such an approach would include careful monitoring for side effects with reduction of the statin dose if indicated.",
"   </p>",
"   <p>",
"    Based upon these data, and the extensive epidemiologic and basic science evidence linking LDL-C levels with CHD risk, many experts and guidelines recommend an approach incorporating high intensity lipid lowering therapy (typically an LDL goal below 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in high risk patients with CHD or in all patients with CHD and CHD risk equivalents.",
"   </p>",
"   <p>",
"    It is worth keeping in mind, however, that the absolute magnitude of the decreased CHD event rates (2.2 percent in TNT; 1.1 percent in IDEAL; 1.2 percent in SEARCH) may not be worth the increased rate of side effects for many patients, particularly given that these are nonfatal events. Furthermore, rates of side effects and discontinuation seen in statin trials are generally much lower than those seen in clinical practice, both because patients who participate in clinical trials are different from the general population, and because many trials use a run-in period to exclude patients who are intolerant of the study medications.",
"   </p>",
"   <p>",
"    A further issue to keep in mind is cost. Generic statins are now available, and the use of high-dose brand name statins in place of slightly less efficacious generic statins may impose a cost burden on patients that is not commensurate with the benefit. The cost to society may also be excessive under some circumstances. An analysis suggested that intensive (high dose) statin therapy in patients with stable CHD may not be cost effective in situations where the incremental cost of such therapy is substantial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of which of the above strategies is chosen for an individual patient, all patients with CHD should be treated with a statin whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     USE OF MEDICATIONS OTHER THAN STATINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite any potential concerns about the lack of benefit of intensive statin therapy on overall mortality discussed above, the evidence for clinical benefits with medications other than statins is far weaker [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/24\">",
"     24",
"    </a>",
"    ]. Statins are the only class of drugs to demonstrate clear improvements in overall mortality in primary and secondary prevention, although follow-up from a clinical trial of niacin suggested some mortality benefits in secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of evidence raising concerns about other lipid-lowering medications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"       cholestyramine",
"      </a>",
"      , clofibrate, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      in primary prevention failed to show mortality benefits and also showed worrisome trends toward an increase in noncardiac deaths. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\", section on 'Effect of early trials on mortality'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A large trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      in patients with diabetes (some of whom had known cardiovascular disease) found a nonsignificant increase in overall mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H30#H30\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'FIELD trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Another large trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      in patients with diabetes (some of whom had known cardiovascular disease, and all of whom were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      ) found no effect of combination therapy with fenofibrate on the primary composite endpoint [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H31#H31\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ACCORD Lipid trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A large trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      for secondary prevention also failed to show any improvement in overall mortality, although cardiac mortality was reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H42#H42\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'VA-HIT trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A meta-analysis of randomized trials (both primary and secondary prevention) found that treatment with fibrates showed a trend toward increased all-cause mortality, an increase in noncardiac mortality, and no effect on cardiovascular mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link&amp;anchor=H3#H3\">",
"       \"Lipid lowering with fibric acid derivatives\", section on 'Mechanism/Efficacy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The combination of a cholesteryl ester transfer protein inhibitor (which raises HDL-C and lowers LDL-C) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      resulted in increased mortality compared with atorvastatin alone [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link&amp;anchor=H29#H29\">",
"       \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\", section on 'CETP inhibition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No adequate clinical endpoint data are available for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      , which inhibits cholesterol absorption. A trial that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      alone with a combination of simvastatin and ezetimibe found no evidence of additional benefit with the combination on the surrogate outcome of change in carotid intima-media thickness [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/31\">",
"       31",
"      </a>",
"      ]. Another trial of combination therapy found that patients treated with niacin plus a statin had fewer cardiovascular endpoints than those treated with ezetimibe plus a statin [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/32\">",
"       32",
"      </a>",
"      ], and another trial found that adding niacin to a statin did not improve outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/33\">",
"       33",
"      </a>",
"      ]. This raises a concern that one possible explanation for the results from these latter two trials could be that adding ezetimibe to a statin might actually worsen outcomes; additional trials are underway that should clarify this issue. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link&amp;anchor=H9#H9\">",
"       \"Lipid lowering with drugs other than statins and fibrates\", section on 'Ezetimibe'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A systematic review concluded that, based on limited evidence, combinations of lipid-lowering agents have not been shown to improve clinical outcomes more than high-dose statin therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?2/59/3002/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, statins are the first choice in virtually all patients with hypercholesterolemia in whom the goal is reduction of primary or secondary cardiovascular risk. If goal LDL-C levels cannot be attained with the use of a statin alone, it is uncertain whether the addition of other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    provides additional clinical benefit, even though LDL-C levels can be reduced further.",
"   </p>",
"   <p>",
"    In the absence of such data in patients with CHD who have not achieved LDL-C goals (whether a goal of &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;2.6",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or a more aggressive LDL goal) despite maximal therapy with a potent statin, reasonable arguments can be made for either of two strategies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the data from primary and secondary prevention trials, as well as other data on statins, are interpreted as suggesting that statins are qualitatively different from other medications used to reduce LDL-C levels, then the trend toward increased mortality seen in primary prevention trials with medications other than statins suggests that the small additional benefits in LDL-C levels that would be achieved by adding another medication to a statin might not translate to improvements in outcome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"       \"Statins: Actions, side effects, and administration\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One might also be concerned about the cost and potential side effects of additional medications. It would therefore be reasonable to use no additional medications in patients who fail to attain LDL-C goals with maximal statin therapy and to instead continue such patients on maximal statin therapy alone.",
"     </li>",
"     <li>",
"      If the data from trials of statins are interpreted as suggesting that the improved mortality is due primarily to their greater efficacy in reducing LDL-C levels, then the use of additional medications in combination with statins to achieve LDL-C goals could be expected to yield additional mortality benefits as long as there is no treatment-related harm that offsets the benefits of LDL-C reduction. It would therefore be reasonable to use additional medications, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      or a bile acid sequestrant, in patients who fail to attain LDL-C goals with maximal statin therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence does not allow a clear distinction between these two strategies, particularly in patients being treated for primary prevention. The practice of most lipid experts and cardiologists is to add a second agent in patients who are being treated for secondary prevention and have not achieved the ATP-III goal LDL-C of 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and some would add a second agent in patients who have not achieved a more aggressive goal of 70",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.8",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    We, however, feel that the current weight of evidence does not support adding a nonstatin medication in a patient who has not achieved a goal LDL-C on maximal dose statin therapy. As mentioned, others disagree. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"       \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major guideline groups, including the US National Cholesterol Education Program (NCEP), the European Society of Cardiology, and the Canadian Medical Association have not published revised guidelines since the results of the TNT and IDEAL trials were published in 2005. In 2004 the NCEP proposed guidelines that take into account the results of PROVE IT-TIMI 22 but not those of TNT. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Intensive therapy with statins'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following recommendations are those of the authors and take into account our interpretation of the current state of evidence and attempt to balance apparent benefits, burdens, and potential risks of cholesterol-lowering therapy. There is general agreement on the approach for acute coronary syndromes (ACS) described below.",
"   </p>",
"   <p>",
"    For other groups of patients, experts looking at the same evidence have come to differing conclusions. This is reflected in the weak (grade 2) recommendations made below regarding the intensity of therapy for patients not experiencing an ACS. Alternative recommendations for these patients are found elsewhere in UpToDate.",
"   </p>",
"   <p>",
"    In broad terms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some experts suggest a goal LDL-C of 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in all patients with established CHD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some experts suggest the use of the doses of statins proven effective in randomized trials without regard to achieved LDL-C. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Statin dose versus goal LDL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some experts suggest use of nonstatin medications in combination with statins for patients who are not at goal on statins alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We highlight these alternative strategies below after each recommendation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Background",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Statin therapy reduces cardiovascular events in both primary and secondary prevention, and also appears to reduce all-cause mortality in most groups studied. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compared with less intensive statin therapy, more intensive statin therapy in patients with stable CHD results in small reductions in cardiovascular events, but appears to have no effect on all-cause mortality. Higher doses of statins may be more likely to produce side effects. In addition, high-dose brand name statins may not be worth the added expense to some patients, when compared with slightly less effective generic statins. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intensive therapy with statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lowering LDL-C with medications other than statins has generally not been proven to reduce overall mortality in either primary or secondary prevention. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Use of medications other than statins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute coronary syndrome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with an acute coronary syndrome be treated with intensive statin therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      80 mg daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link\">",
"       \"Cholesterol lowering after an acute coronary syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stable CHD",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with CHD or a CHD risk equivalent (",
"      <a class=\"graphic graphic_table graphicRef71255 \" href=\"UTD.htm?43/30/44523\">",
"       table 5",
"      </a>",
"      ) who can tolerate statin therapy, we suggest treatment with at least a moderate dose of a statin (eg, 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"       lovastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , or 5 to 10 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      )",
"      <strong>",
"       independent of the baseline LDL-C",
"      </strong>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). More intensive statin therapy to slightly reduce nonfatal cardiovascular events is a reasonable option in patients for whom the additional therapy would not impose undue burdens from side effects or cost. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Putting the evidence together'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients at very high risk for CHD events such as those in the proposed NCEP guidelines (",
"      <a class=\"graphic graphic_table graphicRef54585 \" href=\"UTD.htm?10/56/11147\">",
"       table 2",
"      </a>",
"      ) might also be expected to benefit from more intensive lipid lowering therapy. We suggest that such patients be treated with intensive statin therapy (eg, 40 to 80 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , 20 to 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      ) rather than targeting a goal LDL-C (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Dose-based strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In high-risk patients with an LDL-C above 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.36",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      who are already on a moderate dose of a statin, we suggest increasing to intensive statin therapy (eg, 40 to 80 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      , 20 to 40 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients should be carefully monitored for side effects with reduction of the statin dose if indicated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Dose-based strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of clear evidence, we suggest that patients with stable CHD (any level of risk) who do not tolerate a statin be treated with another lipid-lowering agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Use of medications other than statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the decision is made to target a goal LDL-C, the available evidence does not allow a clear answer on whether to add a second agent in usual risk patients with stable CHD who are unable to achieve that goal with a statin alone. In patients with stable CHD who do not achieve a goal LDL-C on a statin alone, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      adding a second lipid-lowering agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Use of medications other than statins'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other experts, including other authors for UpToDate, would add a second medication in such patients if they are far from their LDL-C goal, but for patients who are nearly at goal would weigh considerations such as side effects and costs in the decision. Some would add a second agent in any patient with CHD who has not achieved an LDL-C goal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the decision is made to target a goal LDL-C, in very high-risk patients who do not achieve a particular goal on intensive statin therapy, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      adding a second lipid-lowering medication (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Use of medications other than statins'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other experts, including other authors for UpToDate, suggest the addition of a second lipid-lowering agent if very high risk patients cannot achieve an LDL-C below 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      with a maximal dose of a potent statin alone, and some would add a second agent in patients who do not achieve an LDL-C below 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/1\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/2\">",
"      Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/3\">",
"      Mills EJ, O'Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of &gt;40 000 patients. Eur Heart J 2011; 32:1409.",
"     </a>",
"    </li>",
"    <li>",
"     Mills EJ. University of Ottawa. Personal communication 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/5\">",
"      Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 2011; 365:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/6\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/7\">",
"      Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/8\">",
"      Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/9\">",
"      Wenger NK, Lewis SJ, Herrington DM, et al. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/10\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/11\">",
"      de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/12\">",
"      LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/13\">",
"      Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/14\">",
"      Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/15\">",
"      Cholesterol Treatment Trialists&rsquo; (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/16\">",
"      Snow V, Aronson MD, Hornbake ER, et al. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004; 140:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/17\">",
"      Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 2006; 145:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/18\">",
"      Hayward RA, Krumholz HM, Zulman DM, et al. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med 2010; 152:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/19\">",
"      Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol &lt;50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/20\">",
"      Rosenson R, Lloyd-Jones D, Working group from the Adult Treatment Panel III of the National Cholesterol Educational Program. Critical appraisal of revised cholesterol guidelines for the very high-risk patient. Expert Rev Cardiovasc Ther 2005; 3:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/21\">",
"      Dale KM, White CM, Henyan NN, et al. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med 2007; 120:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/22\">",
"      SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/23\">",
"      Chan PS, Nallamothu BK, Gurm HS, et al. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation 2007; 115:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/24\">",
"      Studer M, Briel M, Leimenstoll B, et al. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/25\">",
"      Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/26\">",
"      Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/27\">",
"      ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/28\">",
"      Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/29\">",
"      Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154:943.",
"     </a>",
"    </li>",
"    <li>",
"     Pfizer website. Available at: www.pfizer.com (Accessed on December 04, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/31\">",
"      Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/32\">",
"      Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/33\">",
"      AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/59/3002/abstract/34\">",
"      Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009; 151:622.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4557 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_3002=[""].join("\n");
var outline_f2_59_3002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTENSIVE THERAPY WITH STATINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trials providing background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H887355543\">",
"      Trials showing mortality benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trials not showing mortality benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pleiotropic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Statin dose versus goal LDL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dose-based strategy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Minimum LDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Putting the evidence together",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      USE OF MEDICATIONS OTHER THAN STATINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stable CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4557\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4557|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/18/1326\" title=\"figure 1\">",
"      Single LDL outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/36/34383\" title=\"figure 2\">",
"      Replot events vs LDL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4557|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/4/11340\" title=\"table 1\">",
"      ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/56/11147\" title=\"table 2\">",
"      NCEP very high risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/46/10989\" title=\"table 3\">",
"      Proposed ATPIII LDL goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/49/15131\" title=\"table 4\">",
"      PROVE IT prim endpoint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/30/44523\" title=\"table 5\">",
"      CHD risk equivalents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_59_3003="Peak systolic velocity ratios arterial duplex";
var content_f2_59_3003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Peak systolic velocity ratios arterial duplex",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Ratio PSV* at stenotic segment/normal segment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Degree of stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.5-2.0",
"       </td>",
"       <td>",
"        30-49 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.0-4.0",
"       </td>",
"       <td>",
"        50-75 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;4.0",
"       </td>",
"       <td>",
"        &gt;75 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Measuring the degree of stenosis using duplex ultrasound.",
"    <div class=\"footnotes\">",
"     * PSV: peak systolic velocity.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Division of Vascular Surgery at OHSU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_3003=[""].join("\n");
var outline_f2_59_3003=null;
var title_f2_59_3004="Percent prevalent disease";
var content_f2_59_3004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of 15 most prevalent diseases, Texas Department of Criminal Justice, 1997-1998",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percentage of inmates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis infection (history of or current positive tuberculin skin test)",
"       </td>",
"       <td>",
"        20.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td>",
"        9.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        5.2-8.5*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low back pain",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral hepatitis",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Affective disorders",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthritis",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fractures",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cirrhosis",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        2.6-4.8*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hernia",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizophrenic disorders",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epilepsy",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart disease",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV/AIDS",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Prevalence based on data from the National Commission on Correctional Health Care, 2002.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Baillargeon, J, Black, SA, Pulvino, J, Dunn, K. The disease profile of Texas prison inmates. Ann Epidemiol 2000; 10:74.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_3004=[""].join("\n");
var outline_f2_59_3004=null;
var title_f2_59_3005="Estriol by gestational age";
var content_f2_59_3005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68253&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Estriol by gestational age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 301px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    uE3: unconjugated estriol.",
"    <br>",
"     Median maternal serum levels in unaffected pregnancies calculated from in-house data at Women and Infants Hospital, Providence, Rhode Island. These data are representative and not intended or appropriate for use in other laboratories.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_3005=[""].join("\n");
var outline_f2_59_3005=null;
var title_f2_59_3006="Contents: Dermatology";
var content_f2_59_3006=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Dermatology",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Dermatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?35/29/36317\">",
"         Acne and rosacea",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?38/61/39901\">",
"         Bullous disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/27/41405\">",
"         Cosmetic dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/23/38269\">",
"         Cutaneous lymphoma",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?0/33/542\">",
"         Dermatitis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?39/48/40717\">",
"         Dermatologic diagnosis",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?28/0/28685\">",
"         Dermatologic surgery",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?40/2/41005\">",
"         Drug eruptions",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?30/11/30909\">",
"         Genodermatoses",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/44/36557\">",
"         Hair and scalp disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?16/55/17278\">",
"         Infections and infestations",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?7/36/7758\">",
"         Melanocytic lesions and disorders of pigmentation",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/18/14638\">",
"         Nonmelanoma skin cancer and related disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?15/63/16382\">",
"         Other topics in dermatology",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?40/57/41885\">",
"         Papulosquamous disorders",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/41/42654\">",
"         Pediatric dermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?42/53/43869\">",
"         Photodermatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?34/55/35710\">",
"         Skin and systemic disease",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?1/41/1694\">",
"         Urticaria and angioedema",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?26/51/27441\">",
"         What's new in dermatology",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-B8C24466B7-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f2_59_3006=[""].join("\n");
var outline_f2_59_3006=null;
var title_f2_59_3007="Evaluation of lung rejection";
var content_f2_59_3007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Evaluation of possible chronic lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_59_3007=[""].join("\n");
var outline_f2_59_3007=null;
